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 Stimulation of T cells through the T cell receptor (TCR) and co-stimulatory molecules induces a 
diverse set of signaling events leading to T cell activation. Some characteristics of T cell 
activation are cellular proliferation, increase in cell size and changes in metabolic pathways. Our 
work has primarily focused on understanding the roles that PKC and Carma1, MALT1 and 
Bcl10 (the CBM complex) play in T cell activation, specifically, elucidating their requirement in 
distinct T cell signaling pathways. Here, I have shown a requirement for PKC, Carma1 and 
MALT1 in activation of the mTORC1 pathway.  Inhibition of PKC impaired TCR-dependent S6 
phosphorylation and that this requires Carma1 and the MEK/ERK pathways. In the absence of 
Carma1 or MALT1, we noted impaired TCR/CD28-induced stimulation of ribosomal protein S6, 
p70S6K and 4E-BP1 phosphorylation. Pharmacological inhibition of this pathway with a 
MALT1 protease inhibitor (z-VRPR-fmk) impaired T cell proliferation and activation-induced 
glycolysis, as seen by a decrease in oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). Thus, these findings present a novel mechanism for mTORC1 
activation in T cells, through Carma1 and MALT1, leading to cellular proliferation and increased 
glycolysis. Surprisingly, Bcl10 was not required for S6 or S6K phosphorylation in T cells. We 
also demonstrate that MALT1 regulates stimulation dependent S6 phosphorylation in the ABC-
DLBCL subtype. Here, we have identified novel signaling pathways whereby the proteins PKC, 
Carma1 and MALT1 activate the mTORC1 pathway. Our findings will provide new avenues for 
current therapies in dysregulated T cells. 
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1.0  INTRODUCTION 
1.1 TCR SIGNALING 
1.1.1 T cell activation 
Exposure to pathogen induces responses by both arms of the immune system- innate and 
adaptive (1). The innate immune system consists primarily of cells of the myeloid lineage- 
dendritic cells (DC), macrophages, basophils, neutrophils, mast cells and natural killer (NK) cells 
(of lymphoid lineage) (1). These cells are “first responders” and act quickly to prevent the 
deleterious effects of infection with a pathogen (1). On the other hand, cells of the adaptive 
immune system- T and B lymphocytes (T and B cells) are slower to react upon pathogen 
encounter and have a more specialized response (1, 2). Moreover, a key feature of these cells is 
their ability to “remember” previously encountered pathogens, respond accordingly and more 
rapidly upon re-challenge- a phenomenon termed immunological memory (1, 3). T cells 
recognize antigens presented by antigen presenting cells (APC) such as dendritic cells, after 
which they become activated and clonally expand (1). Antigens are recognized via specific and 
diverse T cell receptors (TCR) (1). These receptors induce a variety of signaling cascades 
leading to lymphocyte activation (4, 5). 
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T cells fall in to two main groups- CD4 and CD8 T cells- defined by their expression of 
the transmembrane CD4 or CD8 glycoproteins that associate with the T cell receptor (6). CD4 T 
cells recognize antigen presented by major histocompatibility complex II (MHC II) and 
differentiate into the major T helper subtypes, Th1, Th2, Th17, T regulatory cells (Treg) and T 
follicular helper (Tfh) cells (7, 8). These cells are able to assist other immune cells, releasing 
factors such as cytokines (e.g. IFN-γ, IL-4, IL-12, IL-2, IL-17, IL-23, IL-6, IL-10 and TGFβ), 
which aid in clearance of the pathogen or impair the immune response (in the case of Treg) (7, 
8). CD8 T cells are cytotoxic T cells that directly respond to infected cells through release of 
cytolytic proteins, granzymes and perforin as well production of cytokines, eg. IFNγ (9). 
In addition to stimulation through the TCR, T cells also require engagement of co-
stimulatory receptors for activation (1). The most critical of which is the CD28 receptor, which 
binds the B7 ligand found on APCs (10, 11). Engagement of CD28 with its cognate ligand is 
required for T cell activation, survival, adhesion, differentiation and migration (1, 10-13). TCR 
stimulation in the absence of CD28 stimulation induces an anergic state, whereby T cells are 
hyporesponsive to antigenic challenge (1, 14). Stimulation CD28 induces activation of various 
signaling pathways, specifically the Akt, Ras/ Raf and “inside out” (integrin) signaling pathways 
(11, 12, 15). 
 
1.1.2 Proximal T cell receptor signaling 
Engagement of the T cell receptor with its cognate antigen and CD28 co-stimulation, triggers 
initial activation of the tyrosine kinase Lck in part through dephosphorylation of its inhibitory 
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phosphate group by CD45 (1). Lck is then able to phosphorylate tyrosines in the immunoreceptor 
tyrosine based motif (ITAM) found in the cytoplasmic region of the CD3 and ζ proteins as well 
as and zeta chain associated protein kinase of 70kDa (Zap70), for induction of further 
downstream signaling (16-18). Zap70 facilitates activation of a cluster of proteins through 
phosphorylation of the linker for activation of T cells (LAT), which serves as a central adaptor 
protein in the formation of the LAT ‘signalosome’ (19). Proteins that are bound to 
phosphorylated LAT include phospholipase C gamma (PLCγ), SH2 domain containing leukocyte 
protein of 76kDa (SLP-76), interleukin-2-inducible T cell kinase (Itk), Grb2 and Vav1 (20). 
Formation of this complex is critical for downstream signaling and subsequent activation of T 
cells (20) (Figure 1-1). 
A significant feature of the formation of the LAT signalosome, is the generation of 
second messengers, specifically inositol triphosphate (IP3) and diacylglycerol (DAG), which are 
necessary for potentiation of downstream signaling leading to activation of T cells (21-23). PLCγ 
cleaves phosphatidylinositol 4,5-biphosphate (PIP2), generating IP3 and DAG (24). These second 
messengers are then able to induce Ca2+ release and activate protein kinase C (PKC), both of 
which are required for activation of the essential transcription factors needed for T cell 
activation- nuclear factor of activated T cells (NFAT), nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) and activation protein-1 (AP-1) (22). The LAT signalosome also 
facilitates “inside out” signaling, whereby integrins are activated and upregulated to enhance 
binding to the APC for sustained interaction between the T cell and APC, leading to continued 
signaling (22) (Figure 1-1). 
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1.1.3 Downstream TCR signaling 
NFAT requires Ca2+ in order to be activated by its upstream regulators calmodulin and 
calcineurin (25). Generation of IP3 leads to the release of Ca2+ from the endoplasmic reticulum, 
as well as an influx of extracellular Ca2+ through the CRAC channel, composed of STIM and 
Orai proteins (21). Calmodulin complexed with Ca2+ leads to the activation of the 
serine/threonine phosphatase calcineurin, which dephosphorylates NFAT. Upon 
dephosphorylation, NFAT translocates to the nucleus for transcription of specific genes (25). 
NFAT regulates transcription of IL-2, a cytokine essential for T cell proliferation as well as 
transcription of IL-4, IL-17 and IL-22 (25, 26). NFAT has also been shown to regulate 
transcription of the signature T regulatory (Treg) cell transcription factor Foxp3 (27, 28).  
One of the primary pathways that activate NF-κB is through protein kinase C (PKC), 
Carma1, MALT1, Bcl10 (CBM) complex, leading to the activation of the IκB kinase (IKK) 
complex (29-31). PKC θ is activated by DAG and phosphorylates Carma1, which is then able to 
bind MALT1 and Bcl10, forming the CBM complex (32-35). TRAF6 also associates with this 
complex, and activates TAK1, leading to activation of the IKK complex, through its regulatory 
domain IKKγ (30). The catalytic domain IKKβ phosphorylates the inhibitory protein IκB 
allowing for translocation of the p50 and p65 subunits of NF-κB (36). Work by the Kane group 
has identified an alternate mechanism for activation of NF-κB with T cell receptor stimulation 
and CD28 costimulation through Akt and the CBM complex (37). NF-κB is necessary for 
expression of IL-2, CD25 (IL-2 receptor α chain) and other T cell survival genes necessary for T 
cell differentiation (36). 
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AP-1 consists of two subunits- Fos and Jun, which are regulated by activation via three 
mitogen-activated protein kinase (MAPK) pathways: extracellular signal-regulated kinase 
(ERK), Jun kinase (JNK) and protein of 38 kDa (p38) pathways (22, 38). Initial activation occurs 
through phosphorylation and activation of the TCR-proximal proteins, Ras/ Raf (for activation of 
the ERK pathway) and Ras/ Rac (for activation of the JNK and p38 pathways), which initiate a 
series of phosphorylation events leading to the activation of ERK, JNK, and p38 (22). Upon 
activation of these kinases, Fos and Jun are phosphorylated and translocate to the nucleus to 
regulate T cell transcription (39). Of note, ERK also potentiates activation of AP-1 through 
phosphorylation of Lck, preventing inhibition by SHP1 (40). 
Activation of T cells upon receptor and co-receptor engagement requires a myriad of 
signaling events leading to transcriptional regulation of proteins essential for T cell survival, 
proliferation and differentiation. Immunologists are in the process of trying to tease out all the 
pathways leading to T cell activation and how they directly relate to regulation of the many 
known functions of T cells controlled by TCR and CD28 engagement. Our current knowledge 
has provided a solid foundation for understanding the complex nature of T cell signaling and will 
continue to for future discoveries. 
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Figure 1-1 TCR Signaling 
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1.2 PROTEIN KINASE C 
Protein kinase C (PKC) describes a group of proteins belonging to the Protein Kinase A, G and C 
(AGC) kinase family, which share sequence homology in their catalytic domains (41, 42). Most 
isoforms of PKC are ubiquitously expressed and mediate signaling close to the plasma 
membrane. The importance of the different PKC proteins has been identified through their roles 
in heart disease, cancer, neurological disorders and autoimmunity (41, 42). Understanding the 
mechanism through which PKCs are regulated and the pathways that lie downstream are crucial 
for understanding their roles in different diseases. 
         PKCs are grouped into three different classes- classical, novel and atypical. These 
categories are based on their structure as well as how they are regulated. The classical PKCs 
(PKCα, PKCβI, PKCβII, and PKCγ) require binding of calcium and diacylglyerol (DAG) to their 
regulatory C1 and C2 domains, which promotes activation of their kinase domains (41-43). 
Cleavage of PIP2 by PLCγ generates DAG and IP3, the latter of which induces release of 
cytoplasmic calcium by binding calcium transporters of the endoplasmic reticulum (ER) (23). 
The novel PKCs (PKCδ, PKCε, PKCθ, PKCη), like classical PKCs, require binding of 
diacylglycerol to be activated, but they do not require calcium (42). Of note, use of a synthetic 
analog of DAG, eg. phorbol-myristate- acetate (PMA), is also able to induce activation of 
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classical and novel PKC (44). Unlike the above discussed isoforms, atypical PKCs (PKCλ and 
PKCζ) do not require either DAG or calcium for their activation, and in some cases require 
phosphorylation to be activated (45). 
 
 1.2.1    PKC in T cell receptor signaling 
Most classical and novel PKC isoforms are ubiquitously expressed and induce the 
aforementioned cellular responses (42). PKC θ is a significant signaling molecule linking 
proximal signaling events to transcriptional control of T cells leading to activation.  PKC θ is 
required for TCR- and CD28- mediated activation of NF-κB and NFAT in T cells, through the 
CBM/ IKK complex and MAPK, respectively (29, 35). A unique feature of PKC θ is its 
localization to the so called “immunological synapse” upon engagement of the TCR with 
cognate antigen by peptide/MHC on the APC (46). This localization appears to be important for 
downstream function, specifically NF-κB activation and negative regulation of signaling in Tregs 
(46, 47). 
           A major function of PKC θ in mediating T cell activation is through regulation of the T 
cell cytoskeleton. PKC θ phosphorylates moesin and Wiskott–Aldrich syndrome protein 
(WASP) interacting protein (WIP) both of which regulate actin reorganization to potentially 
allow for sustained interaction of the T cell and APC, in the presence of antigen (48). PKC θ also 
phosphorylates Carma1 in its linker domain allowing for formation of the Carma1 signalosome, 
leading to activation of NF-κB (49). The restricted expression of PKCθ, as well as its differential 
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signaling capabilities compared with other PKC isoforms, makes it an interesting molecule to 
investigate in T cells. 
 
1.2.2 Significance of PKC θ in T cell function  
As expected PKC θ is not only required for activation of T cells but also for CD4 T cell 
differentiation (50). PKC θ has been shown by several groups to be required for Th2 and Th17 
differentiation (50, 51). In the absence of PKCθ, mice displayed reduced Th2 cytokine 
expression in the Th2 mediated model of airway eosinophilia as well as reduced expression of 
the canonical Th2 transcription factor, GATA3 (52). PKC θ KO mice were also shown to 
develop a reduced clinical score of EAE, a Th17- mediated disease model (53). Interestingly, 
PKC θ does not seem to be a critical regulator of Th1 differentiation (54).  
 
 
1.3 CARMA1, MALT1 AND BCL10 
Signaling through the T cell receptor and co-stimulatory molecule CD28 drives a myriad of post- 
translational events, leading to subsequent activation of T cells. A defining characteristic of these 
events is the aggregation of proteins to potentiate downstream signaling, as discussed earlier. Of 
these, Carma1, Bcl10 and MALT1 (the CBM complex) have been shown to be necessary for 
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activation of the NF-κB and JNK pathways (32, 55, 56). Induction of both these pathways is 
required for activation, proliferation and maintenance of T cells (Figure 1-1).  
Upon TCR and co-stimulatory (CD28) engagement, Carma1 recruits Bcl10 and MALT1, 
forming the Carma1 associated signalosome, which serves as a scaffold for other interacting 
proteins (36, 57). Specifically, formation of this complex allows for association of kinases, (eg. 
TAK1, IKK, Akt) and deubiquitinases (eg. CYLD and A20) (30, 31, 37, 58-61). These proteins 
all have catalytic activity and facilitate post-translational modifications necessary for activation 
of the IKK complex and eventual translocation of the p65 and p50 subunits of NF-κB to the 
nucleus (30, 31, 58, 59). Additionally, Carma1 and Bcl10 have been shown to associate with 
TAK1 and MKK7 to induce JNK2 activation and regulate steady-state levels of c-Jun protein 
expression, although the precise mechanism is still unclear (56). 
Over the past twelve years, many articles have been published delineating the 
mechanisms through which Carma1, Bcl10 and MALT1 regulate activation of the NF-κB 
pathway downstream of the TCR. In contrast, the mechanism through which Carma1 and Bcl10 
regulate JNK2 activation and c-Jun expression has yet to be fully defined. More importantly, 
additional TCR-induced signaling cascades that the CBM complex may regulate are yet to be 
identified. The following section will look at the individual components of the CBM complex- 
Carma1, Bcl10 and MALT1- their structure, function and relevance in immunity and disease 
states. 
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1.3.1 Carma1 
1.3.1.1 Structure and Function 
 
Caspase recruitment domain-containing membrane associated guanylate kinase (Carma1) or 
CARD11 is a member of the membrane associated guanylate kinase (MAGUK) group (62). A 
unique feature of Carma1 compared to Bcl10 and MALT1 is its pattern of expression, as it is 
predominantly found in lymphoid tissue, specifically T and B lymphocytes and Natural Killer 
(NK) cells (62). As such, it serves as a critical signaling molecule in the induction of the T and B 
cell response. At this point, Carma1 has been shown to mediate downstream signaling events 
solely by acting as a scaffold for binding of other proteins.  There is no evidence showing kinase 
activity of Carma1 by the guanylate kinase domain (62-65). Here we will look at the different 
domains of Carma1 (Figure 1-2) and their known functions.  
 The caspase recruitment domain (CARD) is expressed in a number of proteins  that 
regulate diverse of cellular processes (66). These “CARD” proteins are able to regulate 
activation of the NF-κB pathway (CARD11, CARD9, CARD14 and CARD8) and  
inflammasome activation (CARD5 and CARD12) (67).The significance of the CARD domain in 
Carma1 (CARD11) in T cells lies with its ability to associate with the CARD domain of Bcl10. 
Upon receptor engagement, Bcl10 is recruited in close proximity to the membrane where is 
interacts with Carma1 via their respective CARD domains (57). Carma1 and Bcl10, along with 
MALT1, are then able to aggregate with other proteins facilitating activation of NF-κB and 
JNK2 activation (65). 
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The linker domain lies between the coiled coil (CC) and the postsynaptic density protein 
[PSD95], Drosophila disc large tumor suppressor [DLG1] and zona occludans-1 protein [ZO1] 
(PDZ) domains (68). Carma1 is primarily regulated by phosphorylation of different residues in 
this region by PKCθ, IKKβ, Akt and CK1 (30, 31, 37, 58-61). Carma1 is phosphorylated by PKC 
θ with TCR stimulation, inducing a conformational change whereby Carma1 goes from a closed 
tertiary structure to an open one (49, 60). The open form of Carma1 is able to bind Bcl10, 
MALT1 and other associated proteins for further downstream signaling (69). Of note, deletion of 
the linker domain generates a constitutively ‘active’ Carma1, which is able to promote continued 
NF-κB activation without upstream cues (69). 
           Other domains of Carma1 include a coiled coil (CC), a PDZ, Src homology 3 (SH3) and a 
guanylate kinase (GUK) domain. These domains primarily function to facilitate association of 
Carma1 with other proteins (eg. CC to MALT1) and localization at the plasma membrane (GUK) 
(69). Of note, ubiquitination of Carma1 in the SH3 and GUK domains leads to degradation and 
subsequent termination of NF-κB and JNK activation, but requires initial Carma1 activation 
(open conformation) (70). This post translational modification is thought to be a negative 
feedback to prevent persistent downstream signaling with continued TCR stimulation.  
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 Figure 1-2 Domains of Carma1 and kinases that phosphorylate Carma1 
 
 
1.3.1.2 Functional role for Carma1 & Significance 
Carma1 regulation of NF-κB activation has been shown to require the TAK1 kinase, activation 
of the IKK complex and subsequent degradation of the inhibitory subunit IkB, allowing nuclear 
translocation of the p65 and p50 subunits of NF-κB (36). Our current understanding of the 
mechanism of TCR-induced NF-κB activation through Carma1 has not been fully defined. 
Regardless, it has been shown by several groups that in the absence of Carma1 T cells display 
impaired stimulation-induced proliferation, cytokine expression and differentiation into different 
T helper subtypes (65). This section will summarize Carma1’s role in T cell activation, 
differentiation and its clinical relevance (Figure 1-3).  
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           Naïve T cells from Carma1-deficient mice have normal thymic development. The 
consequences of Carma1 deficiency become apparent in the periphery, where T cells are unable 
to become fully activated, presumably due to impaired NF-κB and JNK activation. This 
impairment manifests as reduced T cell proliferation, cytokine expression and expression of the 
activation marker CD25 (IL-2Rα) (71). Carma1 has also been implicated in T cell survival, 
through recruitment to the membrane and increased expression of the anti-apoptotic protein   
Bcl-xL (72). Therefore, it is not surprising that Carma1 is also required for differentiation of 
particular T helper subtypes, which require TCR induced activation, co-stimulation and specific 
cytokines.  
           Carma1 regulates Th2 differentiation through modulation of JunB and GATA3 expression 
(65, 73). In the mouse model of asthma, the absence of Carma1 was shown to prevent disease 
onset and also play a critical role in the ability of effector and memory cells to become activated 
(74). Carma1 has also been shown to be necessary for differentiation of Th17 T cells, natural T 
regulatory cells (nTreg) and T follicular helper cells (Tfh) as assessed by expression of the 
signature transcription factors, RORγt, Foxp3 and Bcl-6, respectively (65, 68, 75). 
           Mutations in Carma1 have been implicated in various lymphomas (72, 76). Specifically, 
mutations within the coiled coil domain of Carma1 have been identified in human diffuse large B 
cell lymphoma (DLBCL) (77-79). Recently, it was shown that individuals with Carma1 
deficiency have impaired induction of T cell activation, B cell activation and differentiation, 
leading to an immunodeficient phenotype (80) 
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 Figure 1-3 Hallmarks of Carma1 discoveries 
 
 
1.3.2 Bcl10 
1.3.2.1  Structure and Function 
B cell lymphoma 10 (Bcl10) is a ubiquitously expressed protein in mammalian species (57). It 
was originally identified as a pro-apoptotic protein and later shown to be required for receptor- 
mediated NF-κB activation (33). Bcl10, like Carma1 and MALT1, plays a critical role in the axis  
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between receptor stimulation and downstream signaling, leading to activation of cells of the 
lymphoid and myeloid lineages (58). The following section will focus on Bcl10 structure and its 
functions in T lymphocytes. 
Like Carma1, Bcl10 acts as a scaffolding protein to facilitate binding of other 
catalytically active proteins for activation of the canonical NF-κB pathway, JNK2 and 
stabilization of the AP-1 associated protein, c-Jun upon T cell receptor engagement (56, 66). 
Bcl10 consists of a CARD domain, which binds Carma1 upon TCR stimulation. Bcl10 
constitutively associates with MALT1, which is also recruited to Carma1, to form the CBM 
complex. MALT1 associates with Bcl10 at its serine/threonine (S/T) rich domain (Figure 1-4) 
(69). As mentioned in the previous section, formation of this complex allows for binding of other 
proteins, eg. TRAF6, TAK1, IKKγ  (58). Of note, Bcl10 associates with MALT1 and binds 
Card9 in monocytes (macrophages and DCs) upon receptor engagement (TLRs and Dectin 
receptors) to induce activation of the NF-κB and MAPK pathways (68). Through this, Bcl10 is 
able to positively regulate both the adaptive and innate immune response. Amongst the three 
proteins in the CBM complex, Bcl10 is most heavily regulated by post-translational 
modifications, and these modifications have all been shown to be stimulation dependent. 
Interestingly, most Bcl10 modifications promote inhibition of the NF-κB or JNK pathway 
through degradation of Bcl10 or impairment of CBM complex formation. The E3 ligase, Itch, the 
proteins TAK1, IKKγ (NEMO), CRADD/RAIDD and p62, have all been implicated in 
destabilization of the Bcl10 protein, through ubiquitination, either direct or indirect (69, 81-85). 
Loss of Bcl10 expression significantly impaired NF-κB and/or JNK activation (34, 56).  Of note, 
TCR stimulation is required to induce degradation of Bcl10 through the previously mentioned 
negative regulators (31). 
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Conversely, phosphorylation by CAMKII, partial cleavage by MALT1, and association 
with the E3 ligase Mind Bomb-2 (MIB2) all appear to positively regulate T cell activation, 
through enhanced NF-κB or T cell adhesion leading, to sustained T cell receptor stimulation 
(MALT1 cleavage) (86-88). 
 
1.3.2.2 Functional role for Bcl10 & Significance 
Engagement of the T cell receptor and co-stimulation through CD28 initiates a cascade of 
proximal signaling events, leading to formation of the Carma1, Bcl10 and MALT1 complex (57, 
58). Activation of NF-κB is necessary for T cell proliferation, survival and cytokine expression. 
Additionally, signaling through the Dectin, FcR and Toll-like receptors leads to assembly of the 
Card9, Bcl10 and MALT1 complex, which also promotes and NF-κB and MAPK activation and 
subsequent cytokine and chemokine expression (68).   
           Mice lacking Bcl10 (Bcl10 KO) show a similar phenotype to that of Carma1 KO mice in 
regards to impaired T cell and B cell activation, as well as impairment in formation of B cell 
germinal centers (57). Less is known in regards to the role Bcl10 plays during T cell 
differentiation, but it is predicted that loss of Bcl10 would also have a similar phenotype to that 
seen in the absence of Carma1. Clinically, mutations and overexpression of Bcl10 have been 
identified in MALT lymphomas, evoking continuous NF-κB activation and pro-survival signals 
of lymphoma cells (78, 81, 89, 90).  
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 Figure 1-4: Domains of Bcl10 and associated proteins. P represents phosphorylation 
  
 
 
 
 
 
1.3.3 MALT1 
1.3.3.1 Structure and Function 
Mucosa-associated lymphoid tissue translocation protein 1 (MALT1) was first identified in 
MALT lymphomas, where it is expressed as a fusion protein with cellular inhibitor of apoptosis 
2 (cIAP2) (91). MALT1 serves as scaffolding protein upstream of the NF-κB and the JNK 
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pathways (66). Unlike the other two member of the CBM complex, however, MALT1 has also 
been shown to have catalytic activity, which contributes to downstream function (92). The 
following section will discuss the different domains of MALT1 (Figure 1-4) and their function as 
well as associated MALT1 proteins and the role of MALT1 paracaspase activity. 
 MALT1 contains a death domain (DD) and three immunoglobin (Ig) domains, two of 
which are required for constitutive association with Bcl10. The third Ig domain is located in the 
C-terminus of MALT1, becomes ubiquitinated upon stimulation and also facilitates association 
with IKKγ (36). TRAF6 also associates with MALT1 in a stimulation-dependent manner, 
promoting TRAF6-mediated ubiquitination of MALT1 in its C-terminus, allowing for binding of 
IKKγ (93); however the precise IKKγ binding site in MALT1 has yet to be fully determined.  
Association of TRAF6 is critical for further signaling through the CBM complex to induce 
activation of the NF-κB complex (30, 93). Upon association of TRAF6, the ubiquitylating 
enzymes ubiquitin-conjugated enzyme 13 (UBC13) and ubiquitin-conjugating enzyme E2 
variant (UEV1A), TAB 1/2 and TAK1 are brought together. TAK1 phosphorylates the IKK 
complex, leading to subsequent nuclear translocation of the p50 and p65 subunits of NF-κB and 
gene transcription (94-96). Notably, MALT1 also facilitates binding of the de-ubiquitinases A20 
and CYLD to TRAF6, which are necessary for removal of activation inducing ubiquitin and 
cessation of the NF-κB pathway upon receptor stimulation. 
    MALT1 contains a paracaspase or “caspase-like” domain, which was shown by the 
Beyaert and Thome groups in 2008 to have catalytic activity (95, 97). Similar to other caspases, 
human MALT1 contains two conserved residues Cys 464 and His 415. Mutation of Cys464 
impaired TCR mediated NF-κB activation, revealing a potential requirement for MALT1 caspase 
activity in this pathway. Over the past six years, several substrates for MALT1 have been 
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identified (97). Cleavage of A20, CYLD and Rel-B have all been shown to be necessary for NF-
κB activation, through inactivation of the aforementioned inhibitory proteins (98). MALT1 also 
cleaves Bcl10 near its C-terminus, which promotes adhesion of T cells to the β1 ligand 
fibronectin (97). Other functional studies assessing the role of MALT1 catalytic activity have 
shown cleavage of Caspase 8 and activation of c-FLIPL, leading to T cell proliferation, as well as 
cleavage and inactivation of the RNAse, Regnase, which normally suppresses effector T cell 
function (88, 99). A summary of MALT1 substrates and their functional significance in 
summarized in Table 1-1. 
 
 
 
 
 
Figure 1-5 Domains of MALT1. Ub represent ubiquitination 
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Table 1-1 MALT1 substrates 
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1.3.3.2 MALT1 inhibitors 
As demonstrated in many studies, an understanding of MALT1 catalytic activity, has enabled its 
manipulation in more sophisticated ways. Thus, the discovery that MALT1 is a functional 
paracaspase has led to design of inhibitors for this protein. The first and best defined inhibitor of 
MALT1 is z-VRPR-fmk, designed and originally synthesized by the Thome group (97). This 
irreversible peptide inhibitor was based on the substrate for the metacaspase found in 
Arabidopsis thaliana (97). Use of z-VRPR-fmk was proven to partially inhibit TCR-dependent 
NF-κB activation and IL-2 expression (97). This inhibitor was also shown to prevent MALT1 
direct cleavage of Bcl10 and Rel-B (97, 100). Of note, z-VRPR-fmk had no effect on TCR-
mediated activation of the JNK pathway through Carma1, Bcl10 and MALT1. Thus, MALT1 
paracaspase activity has only been shown to regulate the NF-κB pathway to date. 
   Due to the nature of z-VRPR-fmk, a tetrapeptide conjugated to a ketone, a high 
concentration between 50μM and 150μM is required to see an effect on NF-κB activation, so it is 
a non-feasible drug in the clinical setting (97). As such, other groups have identified and 
generated alternative small molecule inhibitors of MALT1. The Krappman group identified a set 
of phenothiazine derivatives (mepazine, thioridazine and promazine) that serve as non-
competitive MALT1 inhibitors. These compounds are traditional anti-psychotic drugs, but were 
also shown to inhibit NF-κB through MALT1 (101). The Melnick group generated a small 
molecule, irreversible, MALT1 inhibitor (MI-2) which is effective at nanomolar concentrations. 
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MI-2 was found to be effective in NF-κB inhibition both in vitro and in vivo, making it a 
potentially desirable drug for inhibition of MALT1 in vivo (102, 103). 
 
1.3.3.3 Functional Role of MALT1 & Significance 
Similar to Carma1 and Bcl10 KO mice, MALT1 KO displayed impaired activation of peripheral 
T lymphocytes and B lymphocytes (104). As expected, this phenotype can be attributed at least 
in part to the impairment of NF-κB activation in lymphocytes lacking MALT1 (104). Work 
assessing other functional consequences of the absence of MALT1 has shown a requirement for 
MALT1 in differentiation of Th17 cells, but not Th1 cells (96, 105). MALT1 is required effector 
Th17 cytokine expression and in the mouse model of multiple sclerosis, experimental 
autoimmune encephalomyelitis (EAE), MALT1 KO mice are resistant to disease, as compared 
with wild type mice (105). Additionally, other work assessing the role for MALT1 in a Th17 
model revealed a requirement for MALT1 in the anti-fungal response, through the dectin 
receptors in dendritic cells (106). MALT1 is necessary for induction of Th17 polarizing 
cytokines by dendritic cells (106).  
 As described above, MALT1 was first identified for its role association with mucosa 
associated lymphoid tissue (MALT) lymphomas (91). Mutations in MALT1 have been well 
characterized in MALT lymphomas and have been shown to support lymphoma progression 
through aberrant activation of NF-κB, leading to expression of pro-survival signals (89, 91). 
Conversely, patients homozygous for a mutation of MALT1, resulting in no protein expression, 
suffer from combined immunodeficiency, including impaired NF-κB activation and IL-2 
cytokine expression (107, 108). Thus, MALT1 is an essential immunoregulatory protein that is 
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necessary for eliciting an immune response, but overexpression/abnormal expression leads to 
development of hyper-activated lymphoid tissue and cancer. 
  MALT1 is also associated with development and progression of a subset of diffuse large 
B cell lymphomas (DLBCL) (109-111). DLBCL can be divided into two major sub types- 
germinal center B-cell like (GCB) and activated B-cell like (ABC) DBCL, based on their gene 
expression and identification of pathways critical for disease development (112, 113). Carma1, 
Bcl10 and MALT1 have all been implicated as critical regulators in ABC-DLBCL. Mutations in 
Carma1, leading to sustained NF-κB activation, have been identified in this disease (112, 113). 
Recently, the MALT1 inhibitor z-VRPR-fmk has been shown to be efficacious in limiting ABC-
DLBCL growth in vitro, and that this was specific to ABC-DLBCL but not GCB- DLBCL cells 
(109, 114). The small molecule MALT1 inhibitor MI-2 has also been used in treatment of ABC-
DLBCL in vivo. Treatment with this inhibitor in a mouse model of ABC-DLBCL inhibited 
tumor growth (102, 103). 
 
1.4 MTOR SIGNALING 
Mammalian or mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that was 
first identified by virtue of its inhibition by the immuno-suppressive drug rapamycin. This 
compound forms a complex with FK506-binding protein (FKBP12) to inhibit mTOR kinase 
activity (115-118). Through integration of multiple signals from growth factors, amino acids, 
antigenic stimulation and cytokines, mTOR serves as a critical regulator of cellular proliferation, 
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metabolism and growth (115, 118). For the past 15 years rapamycin has been used in the clinic 
as a potent immunosuppressant in the field of organ transplantation (118-120). Additionally, 
rapamycin is used in combination with other drugs for the treatment of some autoimmune 
diseases and cancers (118-123). 
 mTOR exists in two complexes in mammalian systems- mTORC1 and mTORC2. 
mTORC1 consists of mTOR, regulatory-associated protein of mTOR (RAPTOR), mammalian 
lethal with Sec13 protein 8 (mLST8), the proline-rich Akt substrate 40 kDa (PRAS40), and DEP 
domain- containing mTOR-interacting protein (DEPTOR) (118). mTORC2 consists of mLST8, 
DEPTOR, RAPTOR-independent companion of TOR (RICTOR), mSIN1 and protein observed 
with RICTOR (PROTOR) (118, 124, 125). The latter complex lies upstream of mTORC1 and 
directly regulates it, through phosphorylation of the protein kinase Akt at S473 (118). Signaling 
through Akt is one of the primary mechanisms through which mTORC1 is activated (118). 
However, much less is known about how mTORC2 is activated.  
 mTORC1 is activated by signals from growth factor receptors, antigen receptors (T and 
B cells) and amino acids, as well by the Wnt signaling pathway (126-129). Engagement of 
growth factor receptors induces activation of PI3K, which phosphorylates PIP2 to generate PIP3. 
This specific phosphatidylinositol activates the kinase phosphoinositol dependent kinase 1 
(PDK-1), which phosphorylates Akt at T308 along with mTORC2 mediated phosphorylation 
(130, 131).  Active Akt in turn phosphorylates and inactivates the tuberous sclerosis complex 
(TSC1/2) an inhibitor of the direct regulator of mTORC1, Rheb GTPase, leading to mTORC1 
activation. Downstream of mTORC1 are two critical pathways: ribosomal protein p70 S6 kinase 
(p70S6K)/ ribosomal protein (S6) and eukaryotic translation initiation factor 4E-binding protein 
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(4E-BP1)/ eukaryotic translation initiation factor 4E (eIF-4E) pathways, necessary for cellular 
growth and proliferation (130, 131) (Figure 1-6). 
            Amino acids and ATP also serve as activators of mTORC1 through the small Ras related 
GTPases (Rag GTPases) and 5’ adenosine monophosphate-activated kinase (AMPK), 
respectively (126, 128, 132). In the presence of amino acids, the Rag GTPases interact with 
RAPTOR in the mTORC1 complex, facilitating interaction with Rheb, which activates the 
mTOR kinase (128, 132). In conditions of low energy (reduced ATP levels), AMPK is activated, 
which activates the inhibitory complex TSC1/2 leading to inhibition of mTOR (128, 132). Other 
upstream regulators of the mTOR pathway are Ras/Raf, which activate the MEK/ERK pathway 
inducing inhibition of TSC1/2 (133). Alternately, activation of the MAPK pathway also induces 
activation of ribosomal protein p90 S6K, a pathway parallel to mTORC1 that phosphorylates and 
activates S6 (134) (Figure 1-6). Lastly, signaling through cytokine receptor IL-2 has been shown 
to induce activation of the downstream targets of mTORC1, S6K and S6 (129, 135, 136). 
Recently, stimulation through the TNF receptor was also shown to induce mTORC1 activation 
through activation of IKK and inhibition of TSC1/2 (137). 
 Since mTORC1 serves as a central regulator for external signals to coordinate the 
induction of relevant survival responses, its downstream targets- S6 and eIF-4E- are paramount. 
The ribosomal protein S6 is a member of the 40S ribosomal subunit, which is required for 
translation of 5’ terminal oligopyrimidine (5’ TOP) mRNAs, as well as for cellular growth and 
proliferation (138, 139). mTORC1 catalyzes phosphorylation of S6K at T389, a site that is 
necessary for S6K activation (140). Activated S6K is then able to phosphorylate S6 at sites 
S235/236 (human) and S240/244 (mouse), leading to S6 phosphorylation and function in the 40S 
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ribosomal subunit (139). S6 is phosphorylated at multiple sites, however the primary sites, 
235/236 and 240/244, have been shown to be sufficient for S6 activity (139). 
 The eIF4E-binding proteins (4E-BPs) are a set of translational repressors that inhibits the 
formation of the eIF4F complex, by binding to eIF4E (141). There are three 4E-BPs: 4E-BP1, 
4E-BP2 and 4E-BP3 (142).  EIF4E is the rate limiting step of the eIF4F complex formation; 
other members of this complex are eIF4A (ATP-dependent helicase) and eIF4G (scaffold 
protein) (142). Stimulation by growth factors, cytokines and the TCR induces phosphorylation of 
4E-BP1 through mTORC1 (142, 143). Hyperphosphorylation of 4E-BP1 prevents association 
with eIF4E, allowing for complex formation which facilitates translation of 5’ capped mRNAs 
(144). 4E-BP1 is phosphorylated at sites T37, T46, T70 and T65 (145).  
 
 
 
1.4.1 mTOR signaling in T cells 
Engagement of the T cell receptor by MHC  and peptide induces a cascade of signaling events 
leading to activation mTORC2 and mTORC1 (119, 146). As with other receptor-ligand 
interactions, stimulation of the T cell receptor, along with the co-receptor CD28, induces 
activation of PI3K and Akt leading to mTORC1 activation (119, 146). The Cantrell group 
recently proposed an additional mechanism for mTORC1 activation in T cells. They showed that 
activation of the mTORC1 downstream targets, S6K, S6 and 4E-BP1 does not absolutely require 
PI3K/Akt, as inhibitors of these kinases have a modest effect on phosphorylation of these 
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mTORC1 targets (147). Interestingly, PDK1 was shown to be necessary for activation of S6K, 
S6 and 4E-BP1, since in the absence of PDK1 there was little to no phosphorylation of these 
substrates (147). These findings corroborated earlier work showing that Akt is dispensable for 
glycolytic function in activated CD8 T Cells, but PDK is not (147-149). However, the precise 
mechanism of PDK regulation of mTORC1 and its downstream targets is still not fully 
understood. 
             Signaling through the IL-2 receptor has also been shown activate mTORC1 T cells. IL-2 
is a critical cytokine, necessary for T cell survival and proliferation (129, 135). Signaling through 
the IL-2 receptor induces activation of PI3K and Akt, leading to mTORC1 activation and 
downstream function (129, 135). Stimulation of the IL-2 receptor induces association of the 
mTOR protein with Survivin and Aurora B; activation of this pathway regulates G1 to S cell 
cycle entry (150).  
 
 
 
1.4.2 mTOR Function in T cells and Significance 
As with other cell types, mTOR primarily serves as a regulator of T cell proliferation, growth 
and metabolism (119, 150). However, mTORC1 has additional vital functions in T cells, 
specifically the regulation of T cell metabolism as well as the differentiation of both CD4 and 
CD8 T cell subsets (120, 130). 
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Activation of naïve T cells requires a large energy supply for increased cell size, 
proliferation and effector function, and thus, an increase in metabolic output of T cells (131). A 
major regulator of this increase in metabolic output is mTORC1, which promotes increased 
oxidative phosphorylation and a switch to glycolysis (131, 151). mTORC1 regulation of 
glycolysis helps shift T cells from an anabolic state to a catabolic one, through expression of 
glycolytic proteins and glucose and amino acid transporters. Of note, this metabolic switch is a 
characteristic of effector T cells (excluding T regulatory cells), and memory T cells revert to a 
more catabolic state (131, 151). 
 mTORC1 also regulates further T cell differentiation. Inhibition of mTORC1 promotes 
differentiation of memory CD8 T cells, identifying a new target for development of vaccines in 
viral infections (152).  mTORC1 has also been shown to regulate differentiation of Treg (130). 
Inhibition or activation of PI3K/Akt or mTORC1 was shown to increase or impair differentiation 
of T regulatory cells, respectively (153, 154). This additional function of mTORC1 opens a 
variety of possibilities for control of autoimmune diseases by mTOR modulation. 
 As mentioned previously, use of rapamycin is efficacious in immunosuppression for 
prevention of transplant rejection (155). Inhibition of mTORC1 has also been shown as a method 
for treatment in lymphomas in combination with other therapies (122, 156, 157). mTORC1 is a 
central regulator of T cell responses and as such has and will continue to be an attractive target in 
the clinical setting. 
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Figure 1-6 mTOR signaling in T cells 
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1.5 STATEMENT OF THE PROBLEM 
Stimulation through the TCR/CD3 complex and the co-stimulatory molecule CD28 induces a 
cascade of signaling events leading to T cell activation. Our current understanding of the players 
and mechanisms through which this processes occurs is substantial. However, it is clear based on 
the continued pace of new discoveries regarding TCR signaling, that there is still a long way to 
go for us to fully understand all signaling events involved in T cell activation. 
           PKC, Carma1, Bcl10 and MALT1 (the latter three comprising the “CBM” complex) are 
key players in T cell activation, primarily through their activation of NF-κB and JNK pathways 
(56, 58). These proteins are required for activation of peripheral T cells upon antigen encounter, 
as well as for differentiation of CD4 T helper subtypes. PKC θ, Carma1 and MALT1 regulate 
differentiation of Th2, Th17 and natural Treg (nTreg) development (54, 74, 75, 106, 158, 159). 
These characteristics make them critical for adaptive immunity. Thus, understanding the 
molecular mechanisms that drive T cell activation and differentiation through PKC, Carma1, 
Bcl10 and MALT1 is crucial for development and improvement of therapies in the areas of 
infection, cancer and autoimmunity. Based on the fundamental roles that PKC, Carma1, Bcl10 
and MALT1 play in T cell activation and differentiation we hypothesized that these proteins 
regulate other cellular pathways beyond the NF-κB and the JNK pathways.  
         We found that in the absence of Carma1, TCR and CD28 stimulation-dependent S6 
phosphorylation was impaired, suggesting that the CBM complex may regulate the mTORC1 
complex. With this finding, we plan to further investigate the requirement for Carma1, Bcl10 and 
MALT1 in receptor mediated activation of S6 and its upstream regulators S6K and mTORC1, in 
T cells lacking Carma1, Bcl10 or MALT1. Additionally, we will also assess the requirement for 
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PKC in activation of S6 in a TCR/CD28 dependent manner. To understand the functional 
relevance of this alternative pathway of receptor-mediated activation of mTORC1, we also 
intend to assess the ability of T cells to proliferate and modulate their metabolic output upon 
activation in the presence of a MALT1 inhibitor. The results of these studies may identify one or 
more novel signaling pathways leading to the activation of mTORC1 in T cells, thus providing 
alternate sources for targeted therapy regulating mTORC1 activation. Also, characterization of 
additional pathways that PKC, Carma1, MALT1 and Bcl10 regulate may provide new insight 
into their relevance for T cell activation, T cell differentiation and lymphoma progression, 
separate from the NF-κB and JNK pathways, which are currently thought to be their only modes 
of action. 
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2.0  PROTEIN KINASE C REGULATES RIBOSOMAL PROTEIN S6 
PHOSPHORYLATION IN T CELLS 
2.1 INTRODUCTION 
Proximal T cell receptor signaling events, along with stimulation through the co-receptor CD28, 
lead to production of the secondary messengers IP3 and DAG (16). Release of DAG is crucial for 
the downstream activation of protein kinase C (PKC) (29). This kinase induces T cell activation 
in part through phosphorylation and activation of Carma1, leading to NF-κB activation. In 
addition, PKC mediates activation of the MEK/ERK pathway through phosphorylation of its 
upstream regulator Raf, promoting activation of AP-1 (29, 160-162).    
PKC phosphorylates the inhibitory linker domain of Carma1, shifting it from a closed 
conformation to an open one, allowing for association of the proteins MALT1 and Bcl10 and the 
formation of the CBM complex (60). Formation of this complex allows for activation of the IKK 
complex and nuclear translocation of NF-κB (see Chapter 1.3) (60). However, less is known 
about PKC regulation of other pathways necessary for T cell activation, proliferation and 
maintenance. 
Stimulation with phorbol esters (analogues of DAG) induces activation of the mTORC1 
pathway through ERK, presumably through initial activation of PKC (163-166). The MEK/ERK 
pathway has dual roles in the activation of mTORC1 and its downstream target S6, through 
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inactivation of the upstream inhibitory complex TSC1/2, as well as direct phosphorylation of S6 
by p90S6K (163-166). We hypothesize that stimulation of T cells through the TCR and CD28, 
leading to DAG production and PKC activation, might induce similar effects in T cells, i.e. 
activation of mTORC1 and phosphorylation of its downstream target ribosomal protein S6.  
             Our data show that, upon TCR and CD28 stimulation, PKC is able to induce S6 
phosphorylation, and that this in part mediated by the MEK/ERK pathway. We also identified an 
otherwise unappreciated role for Carma1 in induction of S6 phosphorylation, whereby PKC 
requires Carma1 for S6 phosphorylation in T cells.  
 
 
2.2 METHODS AND MATERIALS 
Mice  
C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, Maine). Experimental 
protocols were approved by members of Institutional Animal Care and Use Committee (IACUC) 
at the University of Pittsburgh. 
 
Cell Separation 
CD4+ T cells were isolated from spleen and lymph nodes and were separated by MACS beads 
from Miltenyi Biotech (Auburn, CA) according to the manufacturer’s protocol. The purity of the 
cell population was >90%. 
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Antibodies and Reagents 
Phospho-specific antibodies protein kinase C theta (T538), Alexa Flour 647 conjugated S6 
(S235/236) were obtained from Cell Signaling Technology, Inc. (Danvers, MA). Antibody 
(phycoerythrin (PE)-conjugated) to pERK (202/204) was obtained from BD Biosciences (San 
Jose, CA). Stimulating antibodies, mouse anti-human CD28, hamster anti-mouse CD3 and 
CD28, and phospho–specific antibody to Akt (S473) were obtained from Life Technology 
(Grand Island, NY). HRP-conjugated Protein A was from GE Healthcare (Piscataway, NJ). 
Antibody specific to the Jurkat TCR (C305), purified from C305.2 hybridomas was from ATCC 
(Manassas, VA). Stimulating antibody, Affini-Pure Rabbit Anti-Syrian Hamster IgG and 
secondary antibody, donkey anti-rabbit horse radish peroxidase, were obtained from Jackson 
ImmunoResearch Laboratories Inc. (West Grove, PA). Akt Inhibitor VII (Akti1/2), U0126 and 
Rottlerin were obtained from Calbiochem (Billerica, MA). Bisindolylmaleimide VIII acetate was 
obtained from Enzo Life Sciences (Farmingdale, NY). 
 
Flow Cytometry 
Flow cytometry staining was performed as previously described (167). In short, cells were 
starved in 1% bovine serum albumin (BSA), in PBS for 1 hr at 37°C; for indicated experiments 
cells were also pretreated with inhibitor during starvation period. After stimulation cells were 
fixed with 1.5% paraformaldehyde for ten minutes at r.t. and permeablized with cold methanol 
on ice for fifteen minutes. Cell were then washed three times with buffer (PBS, 1% BSA) and 
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stained with phospho specific antibodies at room temperature for up to 30 minutes. Samples 
were processed on BD LSRII instrument and data were analyzed using FlowJo software. 
 
 
 
Western Blotting  
Cells were lysed with NP-40 lysis buffer (1% NP-40, 1mM EDTA, 20mM TrisHCl, 150mM 
NaCl), containing protease inhibitors (aprotinin, pepstatin, 4-(2-Aminoethyl) benzenesulfonyl 
fluoride (AEBSF) and leupeptin) and phosphatase inhibitors (sodium fluoride, beta-
glycerophosphate and sodium orthovandate). Proteins were resolved on 8-10% SDS-PAGE gels, 
transferred to PVDF membrane and blocked in 4% BSA. Membranes were then probed with 
specified primary antibodies, followed by HRP-conjugated secondary antibodies. Proteins were 
detected using the SuperSignal West Pico ECL substrate from Thermo Scientific and imaged on 
a Kodak Image Station. 
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2.3 RESULTS 
2.3.1 PKC inhibitor bisindolylmaleimide inhibits PKC θ activation 
PKC has been shown in various systems to regulate activation of ribosomal protein S6 (166, 168, 
169). To understand if PKC also regulates S6 phosphorylation upon stimulation through the TCR 
and co-stimulatory molecule CD28, we used the pan-PKC inhibitor bisindolylmaleimide VII 
(BIM) (170). However, due to the promiscuity of some inhibitors we first wanted to assess its 
ability to inhibit another AGC kinase, Akt. The PI3K/Akt pathway, leading to mTORC1 
activation and S6 phosphorylation, is well- characterized at this point (118). To ensure that 
treatment with the PKC inhibitor BIM would inhibit PKC, and not Akt, we assessed Akt 
activation through phosphorylation at S473 (Fig. 2-1A). We noted that treatment with BIM did 
not inhibit Akt phosphorylation, but a previously reported Akt inhibitor (Akti1/2) did (171) (Fig. 
2-1A). We also pretreated Jurkat T cells with the novel PKC inhibitor rottlerin, as PKC θ (a 
novel PKC) is an upstream regulator of T cell signaling events and then assessed 
phosphorylation of Akt (41) (Fig. 2.1B). However, we noted that rottlerin treatment inhibited 
Akt phosphorylation (Fig. 2-1B). As such, we proceeded with BIM for our PKC inhibitor in 
assessment of PKC’s role in activation with TCR and CD28 co-stimulation. 
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 Figure 2-1 BIM inhibits PKC θ phosphorylation in T cells. (A) Jurkat T cells were pretreated 
with varying concentrations of Akti and/or bisindolylmaleimde VII for 1 hour, stimulated with  
anti-TCR/anti CD28 for 15 minutes and Akt (left) and PKC θ (right)  phosphorylation assessed 
by immunoblotting. (B) Jurkat T cells were pretreated with Akti or rottlerin for 1 hr, stimulated 
and Akt phosphorylation assessed. 
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 2.3.2 PKC is required for inducible S6 phosphorylation in T cells 
After confirming the efficacy of the PKC inhibitor BIM, (Fig. 2-1A) we then assessed the 
potential requirement for PKC in S6 phosphorylation upon TCR and CD28 stimulation of T 
cells. We used phosphorylation of S6 at sites S235/236 as our read-out for S6 phosphorylation 
and function (139). We pre-treated Jurkat T cells with BIM, stimulated with anti-TCR/CD28 
Abs, and assessed S6 phosphorylation by flow cytometry. We observed significant inhibition of 
S6 phosphorylation in T cells pretreated with BIM, suggesting that PKC is indeed required for 
TCR/CD28-dependent S6 phosphorylation (Fig 2-2A). We also pre-treated cells with the Akt 
inhibitor and observed inhibition of inducible S6 phosphorylation, but not to the same extent as 
with BIM (Fig. 2-2A). These results were not surprising to us, as the Cantrell group have 
previously provided evidence for alternative regulation of mTORC1, apart from Akt, 
downstream of the TCR (147). To confirm the requirement of PKC in TCR/CD28 mediated 
regulation of S6 phosphorylation in T cells, we also assessed S6 phosphorylation in primary 
CD4+ T cells pretreated with BIM. Similar to results obtained with Jurkat T cells, we noted 
diminished S6 phosphorylation when PKC was inhibited (Fig 2-2B). Our data show that PKC is 
required for TCR/CD28 stimulation-dependent S6 phosphorylation in T cells. 
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 Figure 2-2 PKC regulates S6 phosphorylation in T cells. (A) Jurkat T cells were pretreated 
with Akti or BIM for 1 hr, stimulated for 15 minutes and S6 phosphorylation assessed. (B) 
Primary CD4 T cells were pretreated with BIM for 1 hr, stimulated for 30 minutes and S6 
phosphorylation assessed. All values represent mean + S.E.M of three independent experiments 
(Jurkat T cells) or duplicates of a single experiment (primary cells). Data are representative of 
three independent experiments. 
 
 
 
 
 
 
 
 
 40 
 
2.3.3 PKC regulates S6 phosphorylation in T cells through Carma1 
Engagement of the TCR and co-stimulatory molecule CD28 induces signaling events leading to 
PKC activation, particularly the novel isoform PKC θ. Upon activation of PKC θ, Carma1 is 
phosphorylated, allowing for its association with Bcl10 and MALT1 and subsequent induction of 
NF-κB (50, 58). As we noted a requirement for PKC in TCR/CD28-mediated activation of S6 
(Fig. 2.2), we hypothesized that PKC may be regulating S6 through Carma1. To this end, we 
assessed the ability of T cells to induce S6 phosphorylation (+/- PKC inhibition) in the absence 
or presence of Carma1. Parental Jurkat T cells and Carma1-deficient (JPM 50.6) Jurkat T cells 
were pretreated with varying concentrations of BIM and S6 phosphorylation was assessed after 
stimulation through the TCR and CD28 (Fig. 2-3). Treatment of Jurkat T cells with BIM at 
concentrations as low as 25nM inhibited inducible S6 phosphorylation, and this trend continued 
up to 500 nM BIM (Fig. 2-3). However, pretreatment of Carma1-deficient JPM 50.6 cells with 
BIM did not inhibit inducible S6 phosphorylation, even at higher concentrations of BIM (Fig 2-
3). JPM 50.6 cells show impaired TCR/CD28 inducible S6 phosphorylation compared to parental 
Jurkat T cells and BIM treatment does not further inhibit the residual S6 phosphorylation in JPM 
50.6 cells. Thus, our data show that PKC regulates S6 phosphorylation through Carma1 upon 
TCR/ CD28 stimulation.  
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Figure 2-3 Carma1 is required for PKC regulation of S6 phosphorylation in T cells. Jurkats 
(top) or JPM 50.6 (bottom) cells were pretreated with varying concentrations of BIM for 1 hr, 
stimulated  for 15 minutes and S6 phosphorylation assessed. All values represent mean + S.E.M 
of duplicates of a single experiment. 
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2.3.4 MEK/ERK pathway is required for stimulation dependent S6 phosphorylation in T 
cells 
Upon TCR and CD28 crosslinking, PKC also activates the MEK/ERK pathway through the 
kinase Raf, which lies upstream of MEK and ERK (166). PKC activates mTORC1 by 
inactivation of the inhibitory complex TSC 1/2, through ERK (161, 166). However these 
previous studies all assessed the ability of mTORC1 to become activated after stimulation with 
PMA (164-166) or with cytokine stimulation (172). Our data show that TCR and CD28 
induction of S6 phosphorylation requires PKC and Carma1. We next wanted to understand if 
regulation of S6 phosphorylation after TCR/CD28-mediated T cell activation required the PKC 
downstream target ERK. First, we assessed the effects of the MEK inhibitor U0126 on Jurkat T 
cells. Thus, U0126 inhibited TCR-inducible ERK phosphorylation (Fig. 2-4A). We then assessed 
S6 phosphorylation after U0126 treatment, and found it inhibited S6 phosphorylation, in a 
concentration-dependent manner (Fig.2-4B). We also assessed regulation of S6 phosphorylation 
by the MEK/ERK pathway in primary CD4+ T cells stimulated with anti-CD3/CD28 Ab’s. 
Similar to the result in Jurkat T cells, U0126 inhibited S6 phosphorylation in primary T cells 
(Fig. 2-4B). These findings provide another mechanism through which PKC regulates S6 
phosphorylation in T cells, namely through the MEK/ERK pathway. 
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 Figure 2-4 MEK/ERK pathway is required for stimulation dependent S6 phosphorylation 
in T cells. (A) ERK phosphorylation in Jurkats pretreated with U0126 (1uM) for 1 hour. (B) 
Jurkats were pretreated with varying concentrations of U0126, stimulated with anti-TCR/CD28 
for 15 minutes and S6 phosphorylation assessed. (B) CD4 T cells were pretreated with U0126 
(10uM) for 1 hour, stimulated for 30 minutes and S6 phosphorylation was assessed.  All values 
represent mean + S.E.M of duplicates of a single experiment (C). Data are representative of two 
independent experiments. 
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2.4 DISCUSSION 
Here, we show that induction of ribosomal protein S6 phosphorylation downstream of the TCR 
and co-stimulatory molecule CD28 requires PKC, acting through Carma1 and the MEK/ERK 
pathway (Figure 2-5). Previous work outlining S6 phosphorylation upon TCR and CD28 
stimulation showed a requirement for PI3K/Akt activation, leading to mTORC1 and S6 
phosphorylation, as the primary pathway (146). However, work published by the Cantrell group 
has identified alternate activators of the mTOR pathway, leading to differential responses in T 
cells (147, 173). Here, we have identified another mechanism downstream of the TCR leading to 
S6 phosphorylation. We propose that engagement of the TCR and CD28, which induces 
production of the second messenger DAG, activates PKC, leading to S6 phosphorylation through 
both Carma1and the MEK/ERK pathway. 
Our experiments focused on a broad range of PKC isoforms, using the pan-PKC inhibitor 
BIM. Next, we would like to identify the specific PKC isoform(s) which may potentially regulate 
this pathway, as BIM targets both classical and novel PKC isoforms (see Chapter 1.2). The 
isoform PKC θ is a critical signaling molecule in T cells leading to NF-κB activation and so we 
hypothesize that this isoform may also play a significant role in the induction of S6 
phosphorylation. We initially tried using the novel PKC inhibitor rottlerin, to more specifically 
establish a requirement for PKC θ; however, we noted that this inhibitor was non-specific and 
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had additional kinase targets, namely, Akt (Fig. 2-1B). Thus, we were unable to narrow the 
search for the PKC isoform. For future work, delineating the isoforms involved in S6 
phosphorylation with stimulation, we would like to take genetic approaches, specifically 
knocking down PKC θ expression in T cells and to also use PKC θ KO T cells. 
The requirement for Carma1 in PKC regulation of S6 phosphorylation in T cells does 
indicate that PKC θ is playing a role, since this PKC isoform has been shown to positively 
regulate Carma1 and downstream signaling (49, 60). We are interested in the mechanism through 
which PKC and Carma1 regulates S6, i.e. the potential requirements for Bcl10 and MALT1 (see 
Chapter 3). An interesting facet of this pathway involving Carma1 is that it is predominantly 
found in lymphocytes, so PKC regulation of S6 through Carma1 is mostly limited to 
lymphocytes (57). Thus, there seem to be additional mechanisms of S6 regulation in T cells (and 
potentially B cells), compared with other cell types. 
We have also identified a role for the MEK/ERK pathway in the regulation of S6 
phosphorylation in T cells stimulated through TCR/CD28. We propose two mechanisms 
whereby ERK phosphorylates the inhibitory TSC1/2 complex leading to mTORC1 activation, as 
well as association with p90S6K, which directly phosphorylates and activates S6 (164-166, 168). 
Additional experiments assessing TSC 1/2 phosphorylation and p90S6K activity will need to be 
performed to assess the precise mechanistic connections between the MEK/ERK and S6 
pathways in T cells. 
 Through this work, we suggest additional novel regulators of S6 phosphorylation in 
TCR/CD28-stimulated T cells, namely PKC, Carma1 and MEK/ERK. We envision that PKC 
regulates S6 phosphorylation through Carma1 and MEK/ERK, although the actual mechanism 
needs to be teased out. We propose the presence of intermediary molecules between Carma1 and 
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the MEK/ERK pathway, since activation of the MEK/ERK pathway is unaffected by the absence 
of Carma1 (174). We also do not rule out the possibility that these mechanisms may be working 
through parallel pathways. Our findings contribute to the growing body of knowledge of S6 and 
mTORC1 regulation, specifically in T cell 
 
 
 
Figure 2-5 Model for TCR-dependent PKC regulation of S6 phosphorylation 
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3.0  A CARMA1/MALT1-DEPENDENT, BCL10 INDEPENDENT, PATHWAY REGULATES 
ANTIGEN RECEPTOR-MEDIATED MTOR SIGNALING IN T CELLS 
3.1 INTRODUCTION 
Upon antigenic stimulation, naïve T cells rapidly proliferate, produce cytokines and migrate from 
lymphoid organs, after which they mediate diverse effector functions in tissues. Dysregulation of 
T cell signaling events has been associated with autoimmune diseases and lymphomas, so 
dissection of the mechanisms leading to T cell activation may lead to more efficacious therapies. 
Signaling events initiated by antigen, growth factor and cytokine receptors lead to the activation 
of phosphatidylinositol 3-kinase (PI3K), Akt and the mechanistic target of rapamycin (mTOR), 
to regulate cellular growth and proliferation (175, 176). The 70 kD ribosomal protein S6 kinase 
(p70S6K), which directly phosphorylates ribosomal protein S6, is a key effector of mTOR (139). 
S6 itself is a critical regulator of protein translation, as it is necessary for ribosome biogenesis, 
and is thus an indirect regulator of cellular proliferation (139). Another important substrate of 
mTOR is the translational inhibitor eIF4E-binding protein 1 (4E-BP1), phosphorylation of which 
releases its inhibition of the translation of certain mRNA’s (118) (Figure 1-6). 
In T cells, engagement of the TCR and the co-stimulatory receptor CD28 induces 
activation of PI3K and Akt, which can lead to mTOR, p70S6K and S6 phosphorylation. 
Investigation into the specific roles of S6K and S6 in activation of T cells has revealed a 
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requirement for these proteins in cellular proliferation. Notably, heterozygous expression of S6 
has been shown to limit T cell proliferation, although not cellular size or early activation events, 
after stimulation through the TCR (177). The serine/threonine kinase Akt is a central modulator 
of T cell signaling pathways controlling metabolism, growth, movement, and activation (149, 
178, 179). However, recent studies have suggested that S6 phosphorylation downstream of the 
TCR and CD28 is not strictly dependent on Akt (180, 181).  
Carma1 is an adaptor protein, predominantly found in lymphocytes, that interacts with B 
cell lymphoma 10 (Bcl10) and mucosa associated lymphoid tissue lymphoma translocation 
protein 1 (MALT1) upon antigen receptor stimulation, forming the “CBM” complex. This group 
of proteins is necessary for optimal activation of the NF-κB and c-Jun kinase (JNK) signaling 
pathways (58, 66). In addition, both Carma1 and MALT1 can act as tumor-promoting proteins in 
diffuse large B cell lymphoma (DLBCL) (77, 109, 110). Recent studies on the molecular 
mechanisms by which MALT1 regulates T cell activation have revealed it as a novel 
“paracaspase” (92, 95, 97, 182). Thus, inhibition of MALT1 catalytic activity with the selective 
inhibitor z-VRPR-fmk leads to partially impaired activation of NF-κB (95, 110).  
Here we demonstrate a novel role for Carma1 and MALT1 in the activation of T cells, 
specifically through a signaling pathway leading to mTORC1 activation. Loss of Carma1 or 
MALT1 impaired TCR/CD28-mediated phosphorylation of S6, as well as another downstream 
target of mTOR, 4E-BP1. Surprisingly, by contrast, loss of the Carma1- and MALT1-associated 
protein Bcl10 had no discernable effect on mTORC1 activation. Furthermore, the MALT1 
inhibitor z-VRPR-fmk inhibited both phosphorylation of S6 and proliferation of primary CD4+ 
T cells.  Inhibition of MALT1 activity also impaired the ability of activated T cells to increase 
their metabolic output, which is largely regulated by the mTOR pathway (183-185). Thus, our 
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studies have revealed the existence of a previously unappreciated connection between Carma1, 
MALT1 and mTORC1, leading to enhanced T cell proliferation and metabolism. 
 
 
3.2 METHODS AND MATERIALS 
Mice  
C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, Maine). Carma1 KO 
spleens were a kind gift from Dr. X. Lin (MD Anderson, Texas). Bcl10 KO spleens were a kind 
gift from Dr. L. McAllister-Lucas (University of Pittsburgh). Experimental protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of 
Pittsburgh. 
 
Cell Separation 
CD4+ T cells were isolated from spleen and lymph nodes and separated by MACS beads from 
Miltenyi Biotech (Auburn, CA) according to the manufacturer’s protocol. The purity of the cell 
population was >90%. 
 
Antibodies and Reagents 
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Phospho-specific antibodies to ribosomal protein S6 (S235/236 and S240/244), p70 ribosomal 
protein S6K (T389), mammalian target of rapamycin (mTOR) (S2448), tuberous sclerosis 
complex 2 (TSC2),  4E-BP1 (Thr70),  phospho Akt substrate and Alexa Flour 647-conjugated S6 
(S235/236 and S240/244) were obtained from Cell Signaling Technology, Inc. (Danvers, MA). 
Antibodies to ribosomal protein S6, 4E-BP1 and mTOR were also obtained from Cell Signaling 
Technology, Inc. (Danvers, MA). Antibodies targeting phosphorylated extra cellular signal 
regulated kinase (ERK) 1/2 (T202/Y204) were from BD Biosciences (San Diego, CA). MALT1, 
p70 S6K, Bcl10 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Carma1 
antibody was obtained from ProSci Incorporated (Poway, CA). β-actin antibody was from Sigma 
(St. Louis, MO). Mouse anti-human CD28, hamster anti-mouse CD3 and CD28, PE-conjugated 
anti-CD69 were obtained from Life Technologies (Grand Island, NY). FITC conjugated anti-
mouse CD71 and PE-conjugated anti-mouse CD98 were obtained from BioLegend (San Diego, 
CA). Protein A-HRP was from GE Healthcare (Piscataway, NJ). Antibody specific to the Jurkat 
TCR (C305), purified from the C305.2 hybridoma, was from ATCC (Manassas, VA). Biotin 
conjugated anti-mouse-CD3, -CD4 and -CD28 were obtained from BD Biosciences (San Jose, 
CA). Unconjugated anti-CD3/CD28 antibodies, rabbit anti-Syrian hamster IgG and secondary 
antibody, donkey anti-rabbit-HRP, were obtained from Jackson ImmunoResearch Laboratories 
Inc. (West Grove, PA). MALT1 inhibitor z-VRPR-fmk was obtained from A.G. Scientific (San 
Diego, CA). Recombinant human TNF-α was from R&D Systems (Minneapolis, MN). Phorbol-
12-myristate-13-acetate (PMA), ionomycin, rapamycin and IKK inhibitor II (wedelolactone) 
were from Calbiochem/EMD (Billerica, MA). MEM amino acid solution was from Hyclone 
(Logan, Utah). 
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Cells 
Jurkat T cells, Jurkat T cell mutants (JPM 50.6, MALT1shRNA, Bcl10shRNA, Carma1shRNA 
cells, Control shRNA cells and JPM+ Carma1 cells) and a fast-growing variant of the mouse T 
cell clone D10 were maintained as previously described (15, 167, 171).  
 
Flow cytometry 
Flow cytometry staining was performed as previously described (167). In short, cells were 
starved in 1% bovine serum albumin (BSA), in PBS for 1 hr at 37°C; for indicated experiments 
cells were also pretreated with inhibitor during starvation period. After stimulation cells were 
fixed with 1.5% paraformaldehyde for ten minutes at r.t. and permeablized with cold methanol 
on ice for fifteen minutes. Cell were then washed three times with buffer (PBS, 1% BSA) and 
stained with phospho specific antibodies at room temperature for up to 30 minutes. Samples 
were processed on BD LSRII instrument and data analyzed using FlowJo software. 
 
Luciferase Assays 
Jurkat T cells were transfected with 15 ug of NF-κB luciferase reporter vector by electroporation, 
cultured in complete medium (RPMI, 5% BGS and penicillin/ streptomycin) for 16-20 hrs. Cells 
were pre-treated with inhibitor before stimulation with anti-TCR and anti-CD28, PMA and 
ionomycin or rhTNFα, for six hours. Luciferase assays were performed as previously described 
(15). 
 
 
 
 52 
 
Western Blotting and Immunoprecipitation 
Cells were lysed with NP-40 lysis buffer (1%NP-40, 1mM EDTA, 20mM TrisHCl, 150mM 
NaCl) or with RIPA buffer (1% NP-40, 150 mM NaCl, 25 mM Tris-HCl, sodium deoxycholate, 
SDS) for immune-precipitation (IP) experiments and kinase assays and  protease (aprotinin, 
pepstatin, 4-(2-Aminoethyl) benzenesulfonyl fluoride (AEBSF) and leupeptin) and phosphatase 
inhibitors (sodium fluoride, beta-glycerophosphate and sodium orthovandate) also added. 
Proteins were resolved on 8-10% SDS-PAGE gels, transferred to PVDF membrane and blocked 
in 4% BSA. Membranes were then probed with specified primary antibodies, followed by HRP-
conjugated secondary antibodies. Proteins were detected using the SuperSignal West Pico ECL 
substrate (Thermo Scientific) and imaged on a Kodak Image Station. β-actin was used as a 
loading control for western blot experiments. 
 
In vitro Kinase Assay 
S6K was IP’d from stimulated Jurkat T cells and IPs were washed with kinase buffer (50mM 
Hepes, 200mM NaCl, 1% NP-40 and 1mM EDTA). Beads were incubated for 30 mins at 30°C 
in kinase reaction mix (kinase buffer, GST-S6, and γ-32P-ATP), and reactions were stopped with 
2x Laemmli sample buffer (Bio-Rad, Hercules, CA).   
 
Lentiviral Transduction and Stable Cell Line 
HEK 293T cells were co-transfected with Carma1 shRNA human pLKO.1 lentiviral vector or 
Carma1 in pLEX vector, psPAX2 packaging plasmid and pMO2.G envelope plasmid using 
Effectene reagent (Qiagen, Valencia, CA). Viral supernatant was collected 48 hours later and 
used for generation of the stable cell line. Jurkat T cells were cultured with viral supernatant and 
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complete medium at a 1:1 ratio and replaced with complete medium 24 hrs later. For control 
shRNA cells, Jurkat T cells were transiently transfected with shRNA and placed in selecting 
media two days later. Seeding and selection of positive clones using puromycin (Carma1shRNA 
and JPM + Carma1) or G418 (control shRNA) was as previously described (186). 
 
MTT Assay 
Primary T cell proliferation was assessed using the Cell Titer 96 Aqueous Non-Radioactive Cell 
Proliferation Assay (Madison, Wisconsin). CD4+ T cells were stimulated with anti-CD3 and 
anti-CD28 for indicated times, cells were collected and incubated with MTS/PMS solution for 24 
hrs at 37°C in a humidified, 5% CO2 atmosphere. Absorbance was recorded at 490nm on an 
ELISA plate reader. 
 
Seahorse analysis of T cell respiration 
Naïve CD4+ T cells were isolated from C57BL/6 mice, pretreated with z-VRPR-fmk or 
rapamycin, where indicated and stimulated for 24 hours in a XF24 cell culture microplate 
(Seahorse Bioscience). Cells were then analyzed using the Seahorse XF24 Extracellular Flux 
Analyzer (Seahorse Bioscience) as previously described (187). 
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3.3 RESULTS 
3.3.1 Carma1 regulates phosphorylation of ribosomal protein S6 in T cells 
Our group previously showed that Akt and Carma1 function cooperatively during T cell 
activation, specifically via the transcription factor NF-κB (37). To understand other possible 
downstream effectors of Akt and Carma1, we compared phosphorylation of potential Akt 
substrates between the parental human Jurkat T lymphoma cells, and a variant lacking Carma1 - 
JPM 50.6 (174). Jurkat T cells, JPM 50.6 cells and JPM 50.6 cells re-expressing Carma1 were 
stimulated with anti-TCR and anti-CD28 antibodies. Employing a phospho-Akt substrate 
antibody for western blotting, we detected a prominent band of about 30 kD (note arrow) with 
differing patterns of phosphorylation between parental, mutant and reconstituted Jurkat T cells 
(Fig. 3-1A). Importantly, Akt activation itself is normal in JPM 50.6 cells, as shown by us and 
others (37, 174). However, Akt falls within the large class of AGC kinases and as such shares at 
least partial substrate specificity (RxRxxS/T) with these kinases, notably the protein kinase 
p70S6K (R/KxRxxS/T) (188). Based on the mobility of the band noted in Fig. 3-1A, we 
hypothesized that it may be the ribosomal protein S6, a prominent substrate for p70S6K and a 
downstream effector of the mTOR pathway that is activated by growth factor or T cell receptor 
signaling (115). Thus, we directly assessed activation of S6 induced by the T cell receptor and 
co-stimulatory molecules through phosphorylation at sites S235/236. We confirmed our 
suspicion by flow cytometry with a phospho-specific antibody, which revealed impaired 
induction of S6 phosphorylation in Carma1-deficient JPM 50.6 cells, compared with parental 
Jurkat T cells (Fig. 3-1B). Next, we examined phosphorylation of S6 at an additional cluster of 
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phosphorylated residues - S240/244 - another established readout for S6 phosphorylation (176). 
Again, we noted decreased S6 phosphorylation at these sites in JPM 50.6 cells, compared with 
parental Jurkat T cells (Fig. 3-1C).  We sometimes observed increased basal S6 phosphorylation 
in the JPM 50.6 cells (Fig. 3-1B). To determine whether other pathways of S6 phosphorylation 
were normal in JPM 50.6 cells, we assessed amino acid-dependent stimulation after starvation 
(189), and found that this treatment elicited a similar response in Jurkat T cells and JPM 50.6 
cells, while TCR/CD28-mediated S6 phosphorylation was still impaired (Fig. 3-1D). Thus, the 
cellular response to amino acid levels, which also results in S6K activation and S6 
phosphorylation, does not require Carma1. We also assessed total S6 protein expression in Jurkat 
T cells and JPM50.6 cells and found similar levels of the protein between the cell lines, as 
expected (Fig. 3-1E). These data suggest that regulation of S6 by Carma1 may be relatively 
receptor- or cell type-specific. 
 JPM 50.6 cells were originally derived by chemical mutagenesis of Jurkat T cells  (174). 
To further validate the results obtained with these cells, we specifically knocked down Carma1 
expression in parental Jurkat T cells. We then analyzed phosphorylation of S6 after anti-
TCR/CD28 antibody stimulation of parental Jurkat T cells and Carma1 knock-down cells, 
(“Carma1shRNA,” in which we achieved over 75% knock-down of Carma1 protein). Similar to 
results obtained with JPM 50.6 cells, we found much weaker induction of S6 phosphorylation in 
Carma1 knock-down cells, compared with Jurkat T cells knocked down with control shRNA 
(Fig. 3-1F). To further confirm our findings with primary T cells, we assessed S6 
phosphorylation after PMA/ionomycin stimulation of naive T cells from Carma1 KO and WT 
mice (44). Consistent with the results obtained with cell lines described above, we observed 
impaired induction of S6 phosphorylation in the Carma1 KO T cells (Fig. 3-1G). Taken together, 
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these data reveal the existence of a previously unrecognized role for Carma1 in TCR signaling 
events that regulate phosphorylation of ribosomal protein S6.  
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 Figure 3-1 Carma1 is required for S6 phosphorylation in T cells. (A) Western blot of Jurkat 
T cells, JPM 50.6 cells reconstituted with Carma1 (JPM + Carma1) and JPM 50.6 cells 
stimulated for the indicated times and probed with phospho-Akt substrate antibody. (B-D) Flow 
cytometry histograms of Jurkat T cells and JPM 50.6 cells stimulated with anti-TCR/CD28 (B 
and C) or with amino acids (D) and stained with Alexa-647 conjugated anti-phospho-S6 
(S235/236) (B and D) or phospho-S6 (S240/244) (C), fold induction (relative to un-stimulated). 
(E) Total S6 phosphorylation in Jurkat T cells and JPM 50.6 cells. (F and G) Western blot (left) 
and flow cytometry histograms (right) of Control shRNA cells and Carma1shRNA (F) or WT or 
Carma1 KO primary CD4+ T cells (G) stimulated with TCR/CD28 (F) or PMA/ionomycin (G). 
Values represent mean +/- S.E.M of three independent experiments. Carma1 KO data are 
representative of duplicates from a single experiment. The unpaired Student’s t-test was used to 
determine significance: *p < 0.05; **p <0.01. Data are representative of three independent 
experiments.  
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 3.3.2 Carma1 regulation of p70S6K activation and 4E-BP1 phosphorylation 
Our results showing a requirement for Carma1 in S6 phosphorylation led us to assess activation 
of the upstream regulators of S6, i.e. TSC and mTOR, after TCR and CD28 stimulation (Fig. 3-
2A and B). Our experiments suggested that inducible phosphorylation of TSC2 and mTOR in 
Jurkat T cells and JPM 50.6 cells was similar, although we could only ever achieve modest, if 
any, inducible phosphorylation of mTOR or TSC2 by stimulation with anti-TCR/CD28 
antibodies (Fig. 3-2A and B). To further define the role of Carma1 in mediating phosphorylation 
of S6 and associated pathways, we assessed activity of the kinase immediately upstream of S6 - 
p70S6K (S6K). After TCR and CD28 engagement, this kinase becomes activated, leading to 
phosphorylation of S6 and increased ribosome biogenesis (115). We directly assessed S6K 
phosphorylation in stimulated JPM 50.6 cells and Jurkat T cells expressing Carma1, and also 
noted impaired S6K phosphorylation in the JPM 50.6 cells (Fig. 3-2C). Additionally, we 
performed in vitro kinase assays with S6K isolated from Jurkat T cells and JPM 50.6 cells, using 
GST-S6 as a substrate. Thus, we observed an increase in S6K activity after stimulation of 
parental Jurkat T cells, but not Carma1-deficient JPM 50.6 cells (Fig. 3-2D).   
             Since S6K activity can be regulated by mTOR (115), we investigated this pathway in 
more detail. We then sought to determine if other downstream regulators of mTOR, e.g. 4E-BP1, 
are regulated by Carma1. Investigation of this pathway in JPM 50.6 cells revealed that these cells 
do not express the protein 4E-BP1, or the mRNA encoding this protein (Fig. 3-2E) and (data not 
shown), so we employed the Carma1 knock-down cells described above to determine a possible 
role for Carma1 in regulation of 4E-BP1. Thus, we observed substantially reduced TCR/CD28-
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inducible 4E-BP1 phosphorylation in the Carma1 deficient Jurkat T cells, despite apparently 
normal expression levels of 4E-BP1 itself (Fig. 3-2F). These results indicate that Carma1 also 
plays a role in regulation of mTOR activation, upstream of S6K, S6 and 4E-BP1. 
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 Figure 3-2 Carma1 is required for mTORC1 activation in T cells. (A) TSC2 phosphorylation 
in JPM+Carma1 and JPM 50.6 cells stimulated with anti-TCR/CD28 for indicated times. (B) 
mTOR phosphorylation in Jurkat T cells and JPM 50.6 cells stimulated with anti-TCR/CD28, 
where indicated cells were pretreated with rapamycin (50nM). (C) S6K phosphorylation in 
JPM+Carma1 and JPM 50.6 cells stimulated with anti-TCR/CD28. (D) In vitro kinase assay with 
S6K IP’d from stimulated Jurkat T cells or JPM 50.6 cells, using GST-S6 as an exogenous 
substrate (top panels); S6K auto-phosphorylation is also shown (second row from top). Lower 
rows: western blot of total S6K and GST-S6.  (E) 4E-BP1 expression in Jurkat T cells and JPM 
50.6 cells (F) Jurkat T cells and Carma1shRNA cells were stimulated with anti-TCR/CD28 and 
immunoblotted for phospho 4E-BP1 or phospho S6 (top), graph of densitometry of fold 
induction of normalized values (phospho 4E-BP1, normalized to total 4E-BP1 expression) 
(bottom). 
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3.3.3 Role of MALT1 in TCR/CD28-mediated mTOR signaling 
Activation of NF-κB by Carma1 is mediated by at least two other proteins - Bcl10 and MALT1  
(31). After TCR and CD28 engagement, these proteins associate to form the Carma1, Bcl10 and 
MALT1 (CBM) complex, in which they function to activate downstream pathways, including 
IKK activation (31). Thus, we first sought to determine if MALT1 also plays a role in activation 
of S6, by using T cell lines with greatly reduced expression of MALT1 (190) (Fig. 3-3A). Our 
results assessing differences in mTOR phosphorylation in Jurkat T cells and MALT1shRNA 
cells were similar to our findings in JPM 50.6 cells (Fig. 3-2B), whereby we noted little 
difference between parental Jurkat T cells and MALT1 knockdown cells (Fig. 3-3B). Consistent 
with the findings in JPM 50.6 and Carma1shRNA cells discussed above, we observed impaired 
phosphorylation of S6 after TCR and CD28 stimulation of MALT1shRNA cells (Fig. 3-3C). 
Thus, these results suggest that MALT1, like Carma1, is required for optimal phosphorylation of 
S6 downstream of TCR/CD28 signaling. We also assessed 4E-BP1 phosphorylation in 
MALT1shRNA cells (Fig. 3-3D). Similar to the phenotype observed in Carma1shRNA cells, 
there was greatly reduced 4E-BP1 phosphorylation in cells with reduced MALT1 expression. We 
also assessed S6K phosphorylation and noted little TCR/CD28-dependent phosphorylation in 
MALT1shRNA cells compared with Jurkat T cells (Fig. 3-3E). These data reveal a requirement 
for MALT1 in inducible phosphorylation of the mTOR targets S6K, S6 and 4E-BP1, 
downstream of TCR and CD28. 
To further delineate the mechanism of MALT1-dependent S6K activation, we 
investigated whether these proteins might be present together in a biochemical complex. We IP’d 
MALT1 from T cell lysates and probed for the presence of S6K. Anti-MALT1 IP from the 
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MALT1shRNA cells served as a negative control. Thus, we observed an association between 
MALT1 and S6K in Jurkat T cells (Fig. 3-3F). We were also able to detect mTOR in a complex 
with MALT1 (Fig. 3-3F), although it is still unclear whether any of these interactions is direct. 
Interestingly, however, formation of this complex appears to occur independently of TCR 
signaling, at least in Jurkat T cells.  
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 Figure 3-3 MALT1 is required for mTORC1 activation in T cells. (A) Western blot of 
parental Jurkat T cells, MALT1- and Bcl10-knockdown cells showing MALT1 and Bcl10 
expression. (B) mTOR phosphorylation in Jurkat T cells and MALTshRNA stimulated with anti-
TCR/CD28; cells were pretreated with rapamycin where indicated. (C) Jurkat T cells and 
MALTshRNA cells were stimulated for 15 minutes with anti-TCR/CD28 antibodies and S6 
phosphorylation (S235/236) was assessed by flow cytometry. (D and E) 4E-BP1 (D) and S6K 
(E) phosphorylation in Jurkat T cells and MALTshRNA cells stimulated with anti-TCR/CD28 
and/or PMA/ionomycin (E). (F) MALT1 was immune-precipitated from Jurkat T cells and S6K 
(left) and mTOR (right) association assessed by western blotting. All values represent mean +/- 
S.E.M of three independent experiments. The unpaired Student’s t-test was used to determine 
statistical significance: *p < 0.05; **p <0.01. Data are representative of three independent 
experiments. 
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3.3.4 Role of Bcl10 in TCR/CD28-mediated mTOR signaling 
Since our data revealed a requirement for Carma1 and MALT1 in activation of the mTORC1 
pathway, we next assessed a potential role for the third member of the CBM complex, Bcl10. 
Thus, we sought to determine if Bcl10 also plays a role in activation of S6, by using T cell lines 
with greatly reduced expression of Bcl10 (190) (Fig. 3-3A). We were surprised to observe 
apparently normal S6 phosphorylation in Bcl10shRNA cells (Fig. 3-4A). To confirm these 
results, we stimulated CD4+ T cells isolated from WT or Bcl10 KO mice and found that both 
sets of cells were able to induce S6 phosphorylation at comparable levels (Fig. 3-4B and C). We 
also assessed S6K phosphorylation in WT or Bcl10 KO cells with CD3 and CD28 or 
PMA/ionomycin stimulation and noted similar S6K phosphorylation in both sets of cells (Fig. 3-
4D). Thus, these results suggest that while Carma1 and MALT1 are required for optimal 
phosphorylation of S6 downstream of TCR/CD28 signaling, Bcl10 does not play as critical a role 
in this pathway. The fact that S6 phosphorylation is normal in Jurkat T cells lacking Bcl10 also 
suggests that the impairment in S6 phosphorylation in Carma1-deficient T cells is not merely a 
result of dysregulated NF-κB activity. Nonetheless, we confirmed this more directly by assessing 
the effect of a small molecule inhibitor of IKK on S6 phosphorylation. This compound had no 
effect on CD3/CD28-mediated S6 phosphorylation in primary T cells (Fig. 3-4E), indicating that 
this previously unappreciated pathway is indeed independent of IKK signaling. 
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 Figure 3-4 Bcl10 is not required for S6 phosphorylation in T cells. (A) Parental Jurkat T cells 
and Bcl10 knockdown cells were stimulated for 15 minutes with anti-TCR/CD28 antibodies, and 
S6 phosphorylation (S235/236) was assessed by flow cytometry. (B) Bcl10 expression in WT or 
Bcl10 KO primary cells. (C) Phosphorylation of S6 in PMA/ionomycin-stimulated WT or Bcl10 
KO primary CD4+ T cells. (D) Western blot of stimulated WT of Bcl10 KO primary CD4+ T 
cells and probed with a phospho-S6K antibody. (E) Primary CD4+ T cells were pre-treated with 
the IKK-2 inhibitor, then stimulated for 30 minutes and S6 phosphorylation was assessed. All 
values represent mean +/- S.E.M of three independent experiments. For primary cell experiment 
values represent mean +/- S.E.M. of triplicates (C) or duplicates (E) of a single experiment. The 
unpaired Student’s t-test was used to determine statistical significance: *p < 0.05; **p <0.01. 
Data are representative of three independent experiments, except for panel D, which was 
performed once. 
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3.3.5 MALT1 catalytic activity regulates S6 phosphorylation  
Selective inhibition of MALT1 paracaspase activity with the compound z-VRPR-fmk partially 
inhibits activation of NF-κB, and retards the growth of activated B cell-like diffuse large B cell 
lymphoma (ABC DLBCL) cell lines (97, 100, 110). Consistent with earlier studies, we 
confirmed that this inhibitor partially prevented activation of an NF-κB reporter by TCR/CD28 
stimulation, but not by TNF (Fig. 3-5A). In addition, z-VRPR-fmk had no effect on ERK 
phosphorylation (Fig. 3-5B). However, pre-treatment of Jurkat T cells with z-VRPR-fmk 
impaired mTOR activation, as revealed by decreased S6 phosphorylation (Fig. 3-5D). These 
results were recapitulated in primary murine CD4+ T cells, in which pre-treatment with z-VRPR-
fmk significantly inhibited CD3/CD28-mediated phosphorylation of S6 (Fig. 3-5E). To ensure 
the specificity of this inhibitor we assessed S6 phosphorylation in Jurkat T cells lacking MALT1 
(Fig. 3-3A) and did not see any impairment of S6 phosphorylation in these MALT1 deficient T 
cells with z-VRPR-fmk treatment (Fig. 3-5C). We also assessed S6K phosphorylation in primary 
murine CD4+ T cells with z-VRPR-fmk treatment for up to three days and noted impaired S6K 
phosphorylation compared with untreated cells (Fig. 3-5F). These results reveal a specific role 
for the catalytic activity of MALT1 in regulation of the mTOR pathway in T cells. 
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 Figure 3-5 MALT1 catalytic activity regulates S6 phosphorylation. (A) NF-κB luciferase 
reporter assay of Jurkat T cells pre-treated with z-VRPR-fmk (75 uM) and stimulated with anti-
TCR/CD28, PMA/ionomycin or rhTNF-α for six hours. (B) Jurkat T cells were pre-treated with 
z-VRPR-fmk, stimulated and stained with Alexa-647 conjugated phospho-ERK antibody. (C) S6 
phosphorylation in Jurkat T cells and MALTshRNA cells pretreated with z-VRPR-fmk (75uM) 
and stimulated. (D and E) S6 phosphorylation (S235/236) in Jurkat T cells (C) or primary murine 
CD4+ T cells (D) pre-treated with z-VRPR-fmk before stimulation with anti-TCR/CD28 (Jurkat 
T cells) or anti-CD3/CD28 (CD4+ T cells) antibodies. (F) S6K phosphorylation in stimulated 
CD4+ T cells untreated or pretreated with z-VRPR-fmk. Values represent the mean +/- S.E.M of 
three independent experiments. The unpaired Student’s t-test was used to determine statistical 
significance: * p< 0.05; **p <0.01. Data are representative of three independent experiments. For 
CD4+ T cells, data are representative of triplicates of a single experiment. 
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3.3.6 MALT1 catalytic activity regulates proliferation, but not early activation events, in 
T cells 
Previous studies on the functions of Carma1, Bcl10 and MALT1 in T cell activation have 
predominantly focused on regulation of the transcription factor NF-κB (31, 58, 94). As our data 
indicated a requirement for Carma1 and MALT1 in optimal mTOR activation upon T cell 
stimulation, we next sought to investigate the functional consequences of this novel pathway. 
Heterozygous expression of S6 has been shown to impair proliferation, but not the increase in 
cell size (“blasting”), that follows T cell activation (177). Based on the role of MALT1 in S6 
phosphorylation that we have uncovered, we hypothesized that treatment of naïve T cells with 
the MALT1 inhibitor might phenocopy the effects of reduced S6 expression on T cell 
proliferation. We pre-treated naïve CD4+ T cells with z-VRPR-fmk and stimulated with anti-
CD3 and anti-CD28 antibodies for up to 72 hours and assessed cell number, cell size and 
activation markers. As expected, there was an initial drop in T cell numbers, due to cell death 
induced by the strong polyclonal anti-CD3 stimulation (Fig. 3-6A). While this trend eventually 
reversed by 72 hours in the vehicle-treated T cells, due to T cell proliferation, this reversal was 
not observed in cells treated with z-VRPR-fmk. We also assessed the effects of z-VRPR-fmk on 
T cell proliferation more directly with an MTT assay. This was done in the presence of 
exogenous IL-2 to ensure that the reduction in cell numbers was not due to reduced autocrine 
production of IL-2, as might be expected due to partial inhibition of NF-κB by z-VRPR-fmk. 
Thus, z-VRPR-fmk impaired T cell proliferation by primary CD4+ T cells (Fig. 3-6B), even in 
the presence of exogenous IL-2. Because IL-2 can also activate S6 via the mTOR pathway (191), 
this suggests the existence of a non-redundant TCR-CD28-dependent pathway that requires 
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MALT1 catalytic activity. Consistent with previous findings on S6 (177), we saw that the 
decreased number of z-VRPR-fmk-treated cells was not reflected in altered T cell blasting. Thus, 
cell size, as measured by forward light scattering, was similar between vehicle and inhibitor 
treated T cells (Fig. 3-6C). Also of note, initial activation of MALT1 inhibitor-treated T cells 
was comparable to cells treated with vehicle control, as determined by expression of the early 
activation marker CD69 (Fig. 3-6D). Thus, we have not only shown a requirement for Carma1 
and MALT1 in phosphorylation of S6 and its upstream regulator S6K, but also that this pathway 
controls a known downstream functional target of S6 in T cells, namely cellular proliferation, 
while being dispensable for early activation events.  
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 Figure 3-6 MALT1 regulates T cell proliferation but not early activation events. (A) 
Enumeration of primary murine CD4+ T cells, pre-treated with vehicle or z-VRPR-fmk, and 
stimulated with anti-CD3/CD28 over the course of three days. (B) MTT Assay of stimulated 
CD4+ T cells pre-treated with vehicle or inhibitor in the presence of exogenous IL-2. (C) Size 
(forward scatter) of CD4+ T cells pre-treated with or without inhibitor. (D) Expression of CD69 
on CD4+ T cells stimulated with anti-CD3/CD28 over three days. (C-D) Left - representative 
flow cytometry; right – combined data from duplicate points from a single experiment, 
representative of three that were performed. Values represent mean +/- S.E.M; n=2. The 
unpaired Student’s t-test was used for statistical analysis: * p< 0.05; **p <0.01. 
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 3.3.7 MALT1 regulates the metabolic switch in activated T cells 
Naïve T cells are relatively quiescent with respect to cellular metabolism. However, upon 
activation through the TCR, T cells undergo a dramatic transcriptional and post-transcriptional 
reprogramming (192). The mTOR pathway is a critical regulator of this increase in cellular 
metabolism when T cells shift from a quiescent to activated state (7, 131, 184). As our data 
revealed a role for MALT1 in regulation of the mTOR pathway, we further assessed the 
functional consequences of this effect. To this end, we assessed oxidative metabolism in CD4+ T 
cells stimulated overnight in the presence of the MALT1 inhibitor, z-VRPR-fmk, or the 
mTORC1 inhibitor rapamycin. As expected, we observed a significant increase in oxygen 
consumption in stimulated T cells compared with naïve T cells. Treatment with z-VRPR-fmk or 
rapamycin inhibited the shift to increased metabolic activity (Fig. 3-7A). This effect was 
apparent both in the basal state and after treatment with FCCP, which induces maximal oxygen 
consumption (Fig. 3-7A). We also assessed the role of MALT1 in the upregulation of aerobic 
glycolysis (ECAR). As expected, stimulation of naïve T cells dramatically increased glycolysis 
(Fig. 3-7B). z-VRPR-fmk partially inhibited glycolysis in stimulated T cells, though not to the 
extent of rapamycin (Fig. 3-7B). Upregulation of CD98 (an amino acid transporter) and CD71 
(transferrin receptor) in activated T cells have also been described as mTOR-dependent events 
(193, 194).  However, we noted no difference in the upregulation of these markers in z-VRPR-
fmk treated T cells (Fig. 3-7D). Importantly, and consistent with data discussed above, we noted 
similar CD69 expression under all conditions, indicative of the efficiency of early TCR-mediated 
activation, regardless of MALT1 inhibitor treatment (Fig. 3-7C). 
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 Figure 3-7 MALT1 regulates the metabolic switch in activated T cells. Naïve T cells were 
isolated from C57Bl/6 mice, pretreated with the indicated inhibitors and stimulated in vitro with 
anti-CD3/CD28 antibodies. After 24hrs cells, were analyzed on a Seahorse XF24 analyzer. The 
oxygen consumption rate (OCR) (A) and extracellular acidification rate (ECAR) (B) were 
determined. (C) Equivalent activation of the cells was confirmed by flow cytometry analysis for 
CD69 after conclusion of the Seahorse analysis. (D) CD98 (top) and CD71 (bottom) expression 
in CD4 T cells pretreated with inhibitor and stimulated with antiCD3/CD28 for indicated times. 
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 3.4 DISCUSSION 
 
It was previously thought that TCR and CD28-dependent S6 phosphorylation proceeds 
exclusively through Akt, the TSC1/TSC2 complex, mTOR and S6K (130). However, recent 
studies have introduced additional complexity to this simple linear model, specifically with 
regard to the Akt requirement, as shown recently in CD8+ T cells (149). Here we reveal a 
previously unappreciated role for the proteins Carma1 and MALT1 in signaling downstream of 
mTOR, resulting in phosphorylation of ribosomal protein S6 and the translation regulator 4E-
BP1, during T cell activation (Fig. 3-8). While we have uncovered novel roles for Carma1 and 
MALT1, surprisingly we found that Bcl10 is dispensable for S6 phosphorylation in T cells. 
Although most studies indicate that Carma1 and Bcl10 act in concert to induce T cell activation, 
Carma1 has been shown to disassociate from Bcl10 and bind other proteins (e.g. GAKIN) upon 
TCR engagement (195).  
Our results demonstrate that Carma1 and MALT1 proteins also regulate the 
phosphorylation of another target of mTOR signaling - 4E-BP1. Thus, we present a model 
whereby Carma1 and MALT1 regulate mTORC1 activation and its major downstream targets 
S6K and 4E-BP1 (Fig. 3-8). We found that MALT1 associates with both p70S6K and mTOR, 
consistent with its apparent role in regulating this signaling pathway in T cells, although it is not 
clear if either of these interactions is direct. While mTOR is found in two different protein 
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complexes (mTORC1and mTORC2), we hypothesize that MALT1 specifically associates with 
and regulates mTORC1, since Akt phosphorylation at S473, a direct target of mTORC2, is 
normal in Carma1-deficient T cells (37, 174, 176). Further study will be necessary to fully 
understand the underlying molecular mechanism(s) of this previously unappreciated pathway. 
Given the known role of the CBM complex in the NF-κB pathway, we considered the 
possibility that the impairment of mTOR activation in Carma1 or MALT1 deficient T cells (or 
treatment with z-VRPR-fmk) might be a secondary effect of decreased NF-κB activity. However, 
a small molecule IKK inhibitor did not impair S6 phosphorylation in primary CD4+ T cells, 
suggesting that regulation of S6K and S6 activity by Carma1 and MALT1 is independent of their 
roles in NF-κB activation. Regulation of NF-κB by the CBM complex also occurs in other cell 
types, for example monocytes, where the Carma1 homolog CARD9 regulates activation of NF-
κB (68). Knowing that these proteins have similar functions in other cell types, we are interested 
in determining if activation of mTOR is another pathway that they might regulate.  
We often noted increased basal S6 phosphorylation in Carma1-deficient Jurkat T cells, 
which may be due to a persistent inhibition of mTORC1, as this has been shown to activate 
insulin receptor and, and thus S6 phosphorylation (196). Nonetheless, use of extended nutrient 
starvation and investigation into additional S6 phosphorylation sites (S240/244, which are 
indicative of activation, Fig. 3-1C) confirmed our findings that Carma1 is indeed a positive 
regulator of TCR/CD28-dependent mTOR activation (data not shown). Furthermore, T cells 
from Carma1 KO mice did not have increased basal S6 phosphorylation (Fig. 3-1G). Finally, 
treatment of primary T cells with the MALT1 inhibitor z-VRPR-fmk did not result in increased 
basal S6 phosphorylation, although it did significantly impair CD3/CD28 -induced S6 
phosphorylation. 
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The MALT1 inhibitor z-VRPR-fmk partially decreases NF-κB activation in lymphocytes 
(97). This compound specifically targets the paracaspase domain of MALT1 (as opposed to 
classical caspases), and has provided evidence for catalytic activity of MALT1, which was 
previously thought to act solely as an adaptor protein. Our data provide evidence for another 
function for MALT1 catalytic activity - i.e. activation of mTORC1. The mechanism by which 
MALT1 catalytic activity induces activation of this novel pathway is still unclear, but we 
hypothesize that there might be additional intermediary molecules leading to mTOR pathway 
activation after TCR/CD28 engagement. For example, Kawadler et al., demonstrated that 
MALT1 mediated cleavage of caspase 8 leads to lymphocyte proliferation (197). Since caspase 8 
may also be important for S6K activity (198), caspase 8 is another potential link between 
MALT1 and S6K activation. In addition, MALT1-mediated cleavage of A20 and CYLD have 
been implicated in NF-κB induction (98, 199), although neither has previously been implicated 
in mTOR regulation. A recent study showed that MALT1 can cleave the protein Regnase-1 (aka 
MCPIP1), which normally functions to restrain T cell activation, through destabilization of 
specific mRNA’s, including those that encoding several cytokines (200). Finally, while MALT1 
can cleave Bcl10 close to its C-terminus, this event appears to regulate lymphocyte adhesion but 
not NF-κB (97). Thus, MALT1 is not exclusively a regulator of NF-κB induction, but 
participates in other pathways as well.  
The major functional connections that we have been able to make thus far between the 
MALT1/mTOR pathway involve regulation of T cell proliferation and metabolism, but not early 
activation. The former is consistent with the fact that primary mouse T cells with reduced 
(heterozygous) S6 expression were shown to have decreased cellular proliferation, but normal 
blasting (177). We have also noted that MALT1 activity is dispensable for activation-induced 
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blasting of T cells, as well as upregulation of early activation markers like CD69. The ribosomal 
protein S6 is a critical regulator of protein translation. It is also one of the main downstream 
effectors of mTORC1, and as such is thought to play a critical role in oncogenesis involving 
defects along the mTOR signaling cascade (115, 118, 123, 140). 
Our data have also revealed a role for MALT1 in regulating increased metabolism upon T 
cell activation, a process important for T cells to meet the changing needs of activated and 
proliferating T cells (131). The mTOR pathway is an important regulator of this shift (131, 201). 
Based on the totality of our data, we propose that MALT1 regulation of metabolism in T cells 
occurs at least, in part, through mTOR. We also assessed expression of CD71 and CD98, nutrient 
receptors which facilitate proliferation of T cells upon activation (193, 194). We noted increased 
expression of both after stimulation; however treatment with the MALT1 inhibitor did not impair 
this upregulation (Fig. 3-7D). These data, along with our ECAR results (Fig. 4-7B), suggest that 
treatment with the MALT1 inhibitor, z-VRPR-fmk, does not completely inhibit mTOR 
activation. Thus, we would not expect to see as potent an effect as that seen with the more direct 
mTOR inhibitor rapamycin (Fig. 3-7). Numerous reports have now described additional 
important functions for mTOR signaling pathways in the regulation of peripheral T cell 
differentiation to different effector or regulatory lineages, as well as the regulation of memory T 
cell development (130, 131). For example, mTORC1 promotes the development of pro-
inflammatory Th17 cells, while suppressing the development of anti-inflammatory regulatory T 
cells. Such effects of mTOR in T cells appear to be mediated, at least in part, through regulation 
of the metabolic re-programming that accompanies T cell activation and expansion (120, 131). 
Further studies of these aspects of mTOR function are therefore warranted, as possible additional 
downstream consequences of signaling from Carma1 and MALT1.  
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Figure 3-8 Model for mTORC1 activation in T cells. Carma1 and MALT1 regulate activation 
of mTORC1 with TCR and CD28 stimulation in T cells. 
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4.0  SERINE 231 OF BCL10 REGULATES NF-ΚB ACTIVATION IN T CELLS  
4.1 INTRODUCTION 
Bcl10 is a ubiquitously expressed protein that plays roles in both apoptosis and NF-κB activation 
(33, 58, 202). Bcl10 is essential for T cell activation and Bcl10 KO T cells are unable to 
proliferate. This phenotype is also shared with Bcl10 associated proteins- Carma1 and MALT1. 
Upon TCR engagement and co-stimulation Bcl10 and  its associated protein MALT1, are 
recruited to Carma1, where other proteins, IKK, PDK and TRAF6 bind and activate NF-κB 
through degradation of the inhibitory subunit, IκB (36, 57, 59, 203). In the absence of Bcl10, this 
“signalosome” of proteins is unable to form and NF-κB is unable to be activated through this 
pathway (58, 204). However, NF-κB can be activated through other receptors and pathways, 
specifically through the TNF and TLR receptors (205, 206).   
An area of great interest is the mechanism(s) by which Bcl10 is regulated. Bcl10 is a  
primary target for post translational modifications in the CBM complex. Bcl10 contains a CARD 
domain and a serine/threonine (S/T ) rich domain at its C-terminus. The CARD domain binds to 
Carma1, whilst the S/T domain is ubiquitinated and phosphorylated by multiple proteins (69). 
For example, Bcl10 is phosphorylated by IKK, CamKII, RIP2 and Akt at multiple sites (69) and 
is also ubiquitinated by cIAP-2 and Itch (69, 190). Phosphorylation and ubiquitination lead to 
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contraction of Bcl10 signaling and reduced NF-κB activation (69, 190). On the other hand, 
phosphorylation by RIP2 and Akt both positively regulate Bcl10 and downstream signaling (69). 
Based on our current knowledge of regulation of Bcl10 we were interested in 
identification of other positive regulators of Bcl10 and subsequent NF-κB activation. We have 
identified a previously unappreciated role for serine 231 in T cells. We show that this site is 
necessary for optimal NF-κB activation and IL-2 production. We also show that this site is most 
probably not phosphorylated by Akt but potentially PKC. 
 
 
 
4.2 METHODS AND MATERIALS 
Antibodies and Reagents 
Phospho Akt substrate was obtained from Cell Signaling Technology, Inc. (Danvers, MA). Bcl10 
and MALT1 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). β-actin antibody 
was from Sigma (St. Louis, MO). Antibody specific to the Jurkat TCR (C305), purified from the 
C305.2 hybridoma, was from ATCC (Manassas, VA). Biotin conjugated anti-mouse CD3, CD4 
and CD28 were obtained from BD Biosciences (San Jose, CA). Anti-mouse-CD3 and -CD28 
antibodies were obtained from Life Technologies (Carlsbad, CA). Donkey anti-rabbit-HRP, was 
obtained from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA). Recombinant 
human TNFα was from R&D Systems (Minneapolis, MN). Phorbol-12-myristate-13-acetate 
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(PMA), ionomycin and Akt Inhibitor VII (Akti1/2) were from Calbiochem/EMD (Billerica, 
MA). Bisindolylmaleimide VIII acetate was from Enzo Life Sciences (Farmingdale, NY). 
Phospho-sopecific antibody to serine 231 in Bcl10 was generated as previously described (15). 
 
Cells 
Jurkat T cells, Jurkat T cell mutants, Bcl10sh Clone 3.20, Clone 3.21, Bcl10shRNA, a fast-
growing variant of the mouse T cell clone D10 cell and the human B cell line Raji were 
maintained as previously described (167).  
 
Luciferase Assays 
Jurkat T cells were transfected with 15 ug of NF-κB luciferase reporter vector by electroporation, 
cultured in complete medium (RPMI, 5% BGS and penicillin/ streptomycin) for 16-20 hrs. Cells 
were pre-treated with inhibitor for 30 mins, before stimulation with anti-TCR and anti-CD28, 
PMA and ionomycin or rhTNFα for 6 hours. Luciferase assays were performed as previously 
described (15). 
 
 
Western Blotting and Immunoprecipitation 
Cells were lysed with NP-40 lysis buffer (1% NP-40, 1 mM EDTA, 20 mM Tris-HCl, 150 mM 
NaCl) or with RIPA buffer (1% NP-40, 150 mM NaCl, 25 mM Tris-HCl, sodium deoxycholate, 
SDS) for immune-precipitation (IP) experiments), protease inhibitors (aprotinin, pepstatin, 4-(2-
Aminoethyl) benzenesulfonyl fluoride (AEBSF) and leupeptin) and phosphatase inhibitors 
(sodium fluoride, beta-glycerophosphate and sodium orthovandate). Proteins were resolved on 8-
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10% SDS-PAGE gels, transferred to PVDF membrane and blocked in 4% BSA. Membranes 
were probed with the specified primary antibodies, followed by HRP-conjugated secondary 
antibodies. Proteins were detected using the SuperSignal West Pico ECL substrate (Thermo 
Scientific) and imaged on a Kodak Image Station. β-actin was used as a loading control for 
western blot experiments. 
 
Stable Cell Line 
Jurkat T cells were transiently transfected with Bcl10shRNA (Qiagen, Valencia CA) and two 
days later, seeded in media containing G418 antibiotic. Six weeks later  cells were collected and 
analyzed for Bcl10 knockdown by western blotting.(186) 
 
 
 
4.3 RESULTS 
4.3.1 Generation of Bcl10-deficient Jurkat T cells 
Expression of Bcl10 is required for activation of NF-κB after TCR and CD28 stimulation (33, 
36, 58). Moreover, post-translational regulation of Bcl10 itself has been shown to be a critical 
regulator of NF-κB activation (69, 82, 190, 207). We were interested in further elucidating 
Bcl10’s role in T cell activation. First, we reduced Bcl10 expression in Jurkat T cells, by 
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transfection with Bcl10shRNA. This provided a system where we could re-express wild type and 
mutant forms of Bcl10 and assess the potential effects on NF-κB activation. We generated 
several Jurkat T cell lines stably expressing Bcl10shRNA (data not shown). We found that clone 
3.20 had more than a 50% reduction in Bcl10 expression compared with another clone (3.21) or 
parental Jurkat T cells (Fig. 4-1A). We then assessed the ability of this cell line to induce NF-κB 
activation. We noted that while stimulation with TCR and CD28 antibodies or PMA and 
ionomycin activated an NF-κB luciferase reporter in parental Jurkat T cells, there was 
significantly less NF-κB activation in Bcl10shRNA clone 3.20, as predicted (Fig 4-1B).  
  We then re-expressed wild type Bcl10 in clone 3.20 by transient transfection, in a 
knock-down/add-back experiment. We could detect Bcl10 protein in clone 3.20 cells transfected 
with Bcl10 (Fig 4-1C). However, the NF-κB activity did not reflect re-expression of Bcl10 as 
expected, and we saw no increase in NF-κB in clone 3.20 cells transfected with Bcl10, compared 
with empty vector transfected cells (Fig 4-1D). Of note, clone 3.20 was still capable of NF-κB 
activation, as stimulation with TNF (which does not require Bcl10) induced NF-κB activation 
(Fig 4-1D) (33, 58). 
The reconstitution results for clone 3.20 compelled us to utilize a different system. We 
obtained a Bcl10shRNA T cell line that had previously been validated (190). We transfected 
these Bcl10shRNA cells with a Bcl10-expressing vector, or the empty vector, and assessed NF-
κB activity. Thus, re-expression of Bcl10 increased NF-κB activity in these cells, as compared 
with empty vector-transfected cells (Fig 4-1E). This increase was seen in both unstimulated and 
TCR and CD28-stimulated Bcl10shRNA cells (Fig 4-1E). 
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 Figure 4-1 Generation of Bcl10 knockdown Jurkat T cells. (A and C) Bcl10 expression in 
Bcl10 shRNA stably transfected Jurkats (A) or transiently transfected with wt Bcl10. (B, D) NF-
κB luciferase activity in Bcl10shRNA clones 3.20, 3.21 and Jurkats (B) or clone 3.20 
reconstituted with Bcl10 (D) and stimulated for 6 hours. (E) NF-κB luciferase activity in 
Bcl10shRNA cells reconstituted with Bcl10 and stimulated for 6 hours. All values represent 
mean + S.E.M of triplicates of a single experiment. Data are representative of three independent 
experiments. 
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  4.3.2    Serine 231 of Bcl10 regulates NF-κB activation in T cells 
Previous work identified serine 231 (s321) as a potentially important site for Bcl10 regulation 
after TNF-a stimulation of the breast cancer cell line MCF-7 (208). S231 lies near the C-terminus 
of the Bcl10 and the preceding amino acids, RSRTV, identify S231 as a potential Akt substrate 
(Fig 4-2A) (15). A vector expressing Bcl10 with S231 mutated to alanine had been generated 
previously in the lab. Mutation of serine to alanine prevents phosphorylation of serine 231. To 
understand if phosphorylation of Bcl10 at this site is important for NF-κB activation in T cells, 
we transiently transfected Bcl10shRNA cells with mutant (Bcl10 S231A) or wild type Bcl10 
(Bcl10 wt) and assessed NF-κB activation by luciferase assay. We noted that stimulation through 
the TCR and CD28 induced NF-κB activation in Bcl10shRNA cells expressing either mutant or 
wild type Bcl10. However, wild type Bcl10 was able to induce significantly more NF-κB 
activation, compared with mutant Bcl10 (Fig 4-2B). We also assessed the functional significance 
of serine 231 by IL-2 ELISA. NF-κB drives expression of the cytokine IL-2 (12) and, based on 
our luciferase data, we predicted that mutation of serine 231 would also affect the ability of T 
cells to produce IL-2. We noted that transfection with either wild type or mutant Bcl10 could 
rescue some IL-2 expression in Bcl10 knockdown cells. However, this rescue was significantly 
more efficient in cells expressing wild type vs. Bcl10 (S231A) (Fig 4-2C). Luciferase and IL-2 
ELISA experiments were supplemented with 50ng/ml TNF-α to induce a robust enough readout 
for measurement (Fig 4-2B-C). While the TNF-dependent signal does not require Bcl10, the 
PMA-dependent signal does require Bcl10 and we noted significant differences in the ability of 
wild type Bcl10 to rescue NF-κB activation, compared to mutant Bcl10. 
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 Figure 4-2 Serine 231 of Bcl10 is required for NF-κB activation in T cells. (A) Schematic of 
Bcl10 showing phosphorylation site at S231. (B) NF-κB luciferase activity in Bcl10shRNA cells 
transfected with 10ug of empty vector, Bcl10 (S231A) and Bcl10 (wt) expressing vectors and 
Jurkat T cells (left) and stimulated for 6 hours; western blot of Bcl10 expression in transfected 
Bcl10shRNA cells (right).  (C) IL-2 expression in Bcl10shRNA cells transfected with mutant or 
wt Bcl10; IL-2 expression at 24 hours and Bcl10 expression (top) and expression at 48 hr 
(bottom). All values represent mean + S.E.M of triplicates (luciferase assay) or duplicates 
(ELISA) of a single experiment. Data are representative of  three independent experiments. 
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  4.3.3    Bcl10 is not phosphorylated by Akt in T cells 
Our data showing a requirement for serine 231 in Bcl10-dependent NF-κB activation indicate a 
role for phosphorylation of this site. As mentioned previously, the most probable kinase was Akt, 
based on the sequence around S231 (188). We tested this hypothesis by pretreating D10 mouse T 
cells with an allosteric Akt inhibitor (see chapter 2) at various concentrations, and assessed 
phosphorylation with an Akt phospho-substrate antibody. We immunoprecipitated Bcl10 from 
CD3/CD28-stimulated D10 cells and observed phosphorylation; however, treatment with the Akt 
inhibitor did not alter this phosphorylation (Fig 4-3A). We generated a polyclonal antiserum that 
specifically recognizes the phosphorylated from of Bcl10 at serine 231(15). Using this antibody, 
we assessed Bcl10 phosphorylation at S231 and observed basal phosphorylation even under 
unstimulated conditions (Fig 4-3B). Akt also shares some substrate specificity with PKC, so we 
assessed Bcl10 phosphorylation at serine 231 in the presence of the PKC inhibitor BIM (188). 
Bcl10 phosphorylation was impaired after BIM treatment (Fig 4-3B). Thus, our results suggest 
that Akt does not regulate Bcl10 phosphorylation at serine 231, which instead may be a target of 
PKC. 
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 Figure 4-3 Bcl10 is not phosphorylated by Akt in T cells. (A) Bcl10 IP of  D10s  pretreated 
with varying concentrations of Akti,  stimulated with anti-CD3/CD28 for 30 minutes and probed 
with a phospho Akt substrate antibody. (B)  Bcl10 IP of Jurkats pretreated with BIM for 1 hour, 
stimulated with anti-CD3/CD28 for 30 minutes and probed with a phospho-specific Bcl10 
antibody (panels are from the same blot). Data are representative of three independent 
experiments. 
 
 
 
 
4.4 DISCUSSION 
Engagement of the TCR and CD28 activates the NF-κB pathway through the Carma1, MALT1 
and Bcl10 complex (32-34, 66). MALT1 is the only member of this complex known to have 
catalytic activity, while Carma1 and Bcl10 primarily serve as adaptor proteins, allowing for 
docking of other proteins necessary for NF-κB activation (69, 98). Importantly Bcl10 has been 
shown to be a critical regulator of TCR induced NF-κB, and is regulated in a complex fashion by 
phosphorylation, ubiquitination and degradation (69, 190). Many of these modifications lead to 
attenuation of NF-κB activity (69, 190). Here, we have characterized another mechanism by 
which Bcl10 is regulated in T cells, which translates to effects on NF-κB and IL-2. Thus, we 
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have shown that phosphorylation of serine 231 of Bcl10 is necessary for optimal NF-κB 
activation with TCR and CD28 stimulation.  
The Cheng group had previously identified serines 231 and 218 of Bcl10 as targets of 
Akt phosphorylation after TNF-α stimulation (208). They also showed that Bcl10 forms a 
complex with Bcl13 and translocates to the nucleus (208). Our results using an Akt specific 
inhibitor (Akti 1/2) suggest that Bcl10 is not regulated by Akt, at least in T cells. We assessed 
inhibition of Bcl10 phosphorylation after Akt inhibition in D10 cells and saw no difference in 
phosphorylation profiles between untreated and inhibitor-treated cells. We also assessed Bcl10 
S231 phosphorylation with a phospho-specific antibody and found that Akt inhibitor treatment 
did not impair S231 phosphorylation (data not shown). The study by the Cheng group assessed 
the ability of Akt ability to phosphorylate Bcl10 with TNF-α stimulation in the breast cancer cell 
line MCF-7 (208). It is possible that there is differential signaling to Bcl10 in different types of 
cells and, more importantly, with different modes of stimulation (e.g. TNF receptor versus TCR). 
Little is known about the mechanism by which TNF induces Akt activation leading to NF-κB 
activation, and as such we are unable to conclude whether Bcl10 signaling in T cells parallels 
that of TNF stimulation. More studies assessing direct Bcl10 phosphorylation by Akt (e.g. by in 
vitro kinase assay) after TCR and CD28 stimulation, as well as knockdown of Akt in T cells, will 
be needed to confirm our findings. 
             Interestingly, the Akt phospho-substrate antibody showed that Bcl10 is indeed 
phosphorylated, although this phosphorylation did not seem to be mediated by Akt. This 
antibody recognizes serines/threonines within the consensus sequence RxRxxS/T which also 
shares substrate sequence specificity with other AGC kinases (eg. RSK, S6K and RSK) (188). 
We noted that another AGC kinase, PKC, may regulate S231 phosphorylation. However the 
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PKC consensus substrate specificity, R/KxSxK/R, does not correlate as well with the amino 
acids surrounding 231 (188). BIM serves as a pan-PKC inhibitor, so we are unable to determine 
which PKC isoform may be regulating Bcl10 phosphorylation and downstream function (170).  
Our data suggest another mechanism by which the NF-κB pathway is positively 
regulated, i.e. through phosphorylation of Bcl10 at serine 231. There are many questions that 
remain to be answered about this, including the kinetics of Bcl10 phosphorylation, involvement 
of other Bcl10 phosphorylation sites (i.e. whether there is hierarchical phosphorylation) and 
whether phosphorylation facilitates binding to Bcl10 of other proteins necessary for NF-κB 
activation.  
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5.0  ROLE FOR MALT1 DEPENDENT S6 PHOSPHORYLATION IN ABC-DLBCL 
5.1 INTRODUCTION 
We have shown that MALT1 catalytic activity is necessary for activation of the mTORC1 
complex in T cells. Recently, inhibition of MALT1 is shown to be effective in impairing growth 
and viability of Diffuse Large Cell Lymphoma (DLBCL) cell lines (111, 114). DLBCL is the 
most common form of non-Hodgkin’s lymphoma, accounting for 20-40% of all cases reported 
(77, 209). DLBCL is divided into three major sub-types: germinal center B-cell like (GCB), 
activated B-cell like (ABC) and primary mediastinal B-cell lymphoma. These characterizations 
are primarily based on gene expression profiling of individual DLBCL cases (77, 109, 209). Of 
interest to us is the ABC-DLBCL sub type, which relies on hyper-activation of the NF-κB 
pathway for growth (112, 210). In addition, the proteins Carma1, Bcl10, MALT1 and A20 are all 
implicated in continued activation of NF-κB (77, 209, 211-213). Clinically, ABC-DLBCL shows 
the least favorable prognosis, in comparison with other DLBCL sub types. Thus, understanding 
the mechanism(s) by which ABC-DLBCL maintain their proliferation and survival may lead to 
the development of new and more efficacious therapies. 
Several groups have assessed the effects of genetic and pharmacological manipulation in 
ABC-DLBCL (mostly using cell lines), focusing on Carma1 and/or MALT1. The Staudt group 
has identified mutations in Carma1, specifically in its coiled coil domain, in 10% of ABC-
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DLBCL cases studied (77). These mutations were shown to potentiate NF-κB activation in both 
unstimulated and stimulated B cells (77). Additionally, mutations in the deubiquitinase A20, 
leading to increased NF-κB activation, have been identified in ABC-DLBCL (78). 
More recently, inhibitors of MALT1 paracaspase activity (Chapter 1) have shown 
promise in controlling growth of ABC-DLBCL cell lines, in comparison to other sub-types of 
DLBCL (101, 102, 110, 114). Along with decreased cellular proliferation in the presence of 
MALT1 inhibitors, activation of NF-κB and its downstream targets were also decreased (101, 
102, 110). Based on our findings, showing a requirement for Carma1 and MALT1 in activation 
of the mTORC1 pathway in T cells, we were interested in understanding if this pathway may 
also play a role in ABC-DLBCL.  
 
 
5.2 METHODS AND MATERIALS 
Antibodies and Reagents 
Alexa Flour 647-conjugated antibody to pS6 (S235/236) was obtained from Cell Signaling 
Technology, Inc. (Danvers, MA). Phorbol-12-myristate-13-acetate (PMA), ionomycin was from 
Calbiochem/EMD (Billerica, MA). MALT1 inhibitor z-VRPR-fmk was obtained from A.G. 
Scientific (San Diego, CA). 
 
Cells 
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The DLBCL cell lines, OCI-Ly1, OCI-Ly3 and OCI-Ly7, were from Dr. Mark Minden (Ontario 
Cancer Institute, Ontario, Canada) were maintained in IMDM media (Life Technologies, Grand 
Island, NY), with 10% Bovine Growth Serum and 1% penicillin/ streptomycin (Mediatech, 
Herndon, VA). 
 
Flow Cytometry 
Flow cytometry staining was performed as previously described (167). In short, cells were 
starved in 1% bovine serum albumin, in PBS for one hr at 37°C; for indicated experiments cells 
were also pre-treated with inhibitor during starvation period. After stimulation cells were fixed 
with 1.5% paraformaldehyde at RT for 15 minutes and permeablized with cold methanol on ice. 
Cells were then washed three times with buffer (PBS, 1% BSA) and stained with phospho-
specific antibodies at room temperature. Samples were analyzed on a BD LSRII. 
 
 
 
5.3 RESULTS 
5.3.1 z-VRPR-fmk does not inhibit basal S6 phosphorylation in DLBCL cells  
To address a potential role for MALT1 in regulating the mTORC1 pathway, we first assessed the 
ability of a MALT1 inhibitor (z-VRPR-fmk) to inhibit S6 phosphorylation in DLBCL cell lines. 
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We utilized the GCB-DLBCL cell line OCI-Ly1 and OCI-Ly7, and the ABC-DLBCL cell line 
OCI-Ly3. We pretreated these cells for one hour with z-VRPR-fmk and assessed S6 
phosphorylation. We did not observe any effect on S6 phosphorylation in these particular cell 
lines (Fig. 5-1A) after treatment with the MALT1 inhibitor. In previously published work by the 
Thome group, treatment for extended periods of time with z-VRPR-fmk was shown to inhibit 
cellular proliferation in ABC-DLBCL cell lines (100, 110). As such, we also assessed S6 
phosphorylation in DLBCL cell lines pretreated with z-VRPR-fmk for 24 and 48 hours (Fig. 5-
1B). Similar to the results above with short-term pretreatment, there was no impairment in S6 
phosphorylation after extended inhibitor treatment. However, we did note significantly higher S6 
phosphorylation in the ABC-DLBCL cell line OCI-Ly3 with MALT1 inhibitor treatment, which 
was not seen in the GCB-DLBCL cell line OCI-Ly1 and OCI-Ly7 (Fig. 5-1B). These results 
show that inhibition of MALT1 catalytic activity with z-VRPR-fmk does not impair basal S6 
phosphorylation in DLBCL cells. 
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Figure 5-1 z-VRPR-fmk does not inhibit basal S6 phosphorylation in DLBCL cells. (A)  
Histograms (left) or mean fluorescence intensity (MFI) (right) of S6 phosphorylation in GCB-
DLBCL cell lines (OCI-Ly1, OCI-Ly7) and ABC-DLBCL cell line (OCI-Ly3) pretreated for 1 hr 
with z-VRPR-fmk. (B) Same as A, but pretreated for 24 hours (top) or 48 hours (bottom) with z-
VRPR-fmk. All values represent mean + S.E.M of duplicates of a single experiment.  
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5.3.2 Induction of S6 phosphorylation in DLBCL after PMA and Ionomycin stimulation 
Although we did not observe an impairment of S6 phosphorylation after MALT1 inhibition in 
unstimulated cells, we hypothesized that treatment with the inhibitor may only be effective when 
the DLBCL cell lines are stimulated. This was based on our findings in T cells (Chapter 3) where 
t z-VRPR-fmk inhibited S6 phosphorylation in a human T cell line cells and in primary mouse T 
cells, after TCR/CD28 stimulation (Chapter 3). PMA activates PKCs (Chapter 1) through 
activation of the Ras/ Raf pathway and ERK (214-216), but the ability of PMA and ionomycin to 
induce S6 phosphorylation in DLBCL cell lines has not yet been reported. We stimulated the 
three DBLCL cell lines described above with PMA and ionomycin for up to one hour, and noted 
increased S6 phosphorylation at all time points assessed - 15, 30 and 60 minutes (Fig. 5-2). We 
found different kinetics for S6 phosphorylation with the different cells lines, but consistently 
found increased S6 phosphorylation at 30 minutes (Fig. 5-2). Our results show that stimulation 
with PMA is indeed able to induce S6 phosphorylation in the DLBCL cells tested.  
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 Figure 5-2 Induction of S6 phosphorylation in DLBCL after PMA and ionomycin 
stimulation. DLBCL cell lines were stimulated for 15, 30 and 60 minutes with PMA (50ng/ml) 
or ionomycin (1uM) and S6 phosphorylation assessed by flow cytometry- histograms (top), MFI 
(bottom). 
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5.3.3 MALT1 regulates inducible S6 phosphorylation in ABC-DLBCL cells 
After determining a suitable time point (30 minutes) for induction of S6 phosphorylation with 
PMA/ionomycin stimulation (Fig. 5-2), we next assessed the effect of MALT1 inhibition on 
inducible S6 phosphorylation. OCI-Ly1 and OCI-Ly3 cell lines were pre-treated with the 
MALT1 inhibitor z-VRPR-fmk, stimulated with PMA/ionomycin, and S6 phosphorylation was 
assessed by flow cytometry. We did not observe a consistent difference between these cell lines 
in the levels of basal S6 phosphorylation, nor was basal S6 phosphorylation in either cell line 
significantly affected by z-VRPR pre-treatment (Fig. 5-3A). Interestingly, however, 
PMA/ionomycin-induced S6 phosphorylation was reduced by z-VRPR-fmk in ABC-type OCI-
Ly3 cells, but not in OCI-Ly1 (GCB) cells (Fig. 5-3A). We also assessed another GCB-DLBCL 
cell line (OCI-Ly7) and, consistent with the above results, did not see any impairment in 
PMA/ionomycin-inducible S6 phosphorylation by MALT1 inhibitor treatment (Fig. 5-3B). 
These findings suggest that S6 is a previously unknown downstream target of dysregulated 
MATL1 activity in ABC-DLBCL, which may further our understanding of molecular events that 
contribute to this sub-type of lymphoma.  
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 Figure 5-3 MALT1 regulates inducible S6 phosphorylation in ABC-DLBCL cells. (A) OCI-
Ly1 (GCB) and OCI-Ly3 (ABC) DLBCL cells were pre-treated with z-VRPR-fmk (75 mM) for 
four hours and stimulated with PMA (50 ng/mL) and ionomycin (1 mM) for 30 minutes. S6 
phosphorylation was assessed by flow cytometry. (B) Same as (A) using OCI-Ly7 (GCB) with 
OCI-Ly3 (ABC) DLBCL. Data are duplicate points from a single experiment, representative of 
three that were performed. Values represent mean +/- S.E.M; n=2. Unpaired Student’s t-test was 
used for statistical analysis, * p< 0.05; **p <0.01. 
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5.4 DISCUSSION 
Carma1 and MALT1 play key roles in the progression of DLBCL, specifically the ABC type. 
We found that a MALT1 inhibitor reduced S6 phosphorylation in an ABC-DLBCL cell line, but 
not two different GCB-DLBCL lines, consistent with published data (110, 114). We were not 
surprised to find that the effect of z-VRPR-fmk on S6 phosphorylation in the ABC-DLBCL cells 
was somewhat modest, as other published data have only shown partial inhibition of NF-κB in 
these cells, even with higher concentrations of z-VRPR-fmk (110, 210). Additionally, ribosomal 
protein S6 is regulated by a multitude of other pathways, so the effects of MALT1 on this 
pathway may be at least partially redundant with other regulators.  
             We were initially surprised by our preliminary results showing no inhibition of S6 
phosphorylation by z-VRPR-fmk in the ABC-DLBCL cell line OC-Ly3 under unstimulated 
conditions (Fig. 5-1). Based on published work assessing the effects of z-VRPR-fmk on DLBCL 
growth, we expected to observe some inhibition of S6 phosphorylation (110, 114). However, our 
results showing z-VRPR-fmk inhibition of inducible S6 phosphorylation are similar to our 
findings in T cells (Chapter 3). These results indicate that MALT1 needs to be “activated” 
through PKC and Carma1 for eventual phosphorylation of S6, and that this maybe specific to 
ABC-DLBCL, which already displays CBM dysregulation. 
            We did note increased basal S6 phosphorylation in OCI-Ly3 cells treated for longer time 
points (24 and 48 hours, Fig. 5-1B). This may be due in part to feedback inhibition through 
mTOR, which has been shown to potentiate Akt activation through expression of insulin receptor 
substrate (IRS) and continued mTOR signaling (217, 218). Under basal (or steady state) 
conditions, continued inhibition of the mTORC1 pathway by z-VRPR-fmk may activate this 
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feedback pathway, leading to increased S6 phosphorylation. Thus, further studies assessing IRS 
expression and Akt activation with z-VRPR-fmk treatment will need to be performed. 
            More recently, small molecule inhibitors of MALT1 have also shown substantial efficacy 
in inhibiting in vitro growth of ABC-DLBCL, but not GCB-DLBCL, which was attributed to 
differential activation of the NF-κB pathway (101, 102, 219). Thus, it will be of interest to 
further investigate the role(s) MALT1 may play in ABC-DLBCL progression, specifically in the 
mTORC1 pathway. 
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6.0  SUMMARY AND DISCUSSION 
Induction of T cell responses upon TCR and co-stimulatory engagement involves a myriad of 
signaling events leading to transcriptional, translational and post-translational changes (4, 10). 
Understanding these events is critical for deciphering how T cells work in normal and 
pathological settings. Here, we have identified a previously unappreciated role for the proteins 
PKC, Carma1 and MALT1 in the induction of the mTORC1 pathway, downstream of TCR and 
CD28 engagement. Our findings provide new insight into the additional mechanisms through 
which the mTORC1 pathway is regulated in T cells and uncover alternative functions for 
Carma1 and MALT1, beyond their known roles in the NF-κB and JNK2 pathways. 
 
6.1 TCR-DEPENDENT S6 PHOSPHORYLATION REQUIRES PKC 
 Phosphorylation of the ribosomal protein S6 after TCR and CD28 stimulation requires PKC, 
Carma1 and the MEK/ERK pathways. Based on previously published work on receptor tyrosine 
kinases (RTKs), PKC has been shown to activate the mTORC1 pathway and also to activate S6 
independently of mTORC1, through p90S6K (134, 161, 220-223). However, the mechanism by 
which PKC regulates S6 phosphorylation after TCR stimulation has not been investigated. The 
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majority of published findings on activation of S6 after TCR and CD28 stimulation are 
consistent with PI3K/Akt leading to mTORC1 and subsequent S6 and 4E-BP1 activation. 
However, studies by the Cantrell group have suggested the existence of an alternate pathway that 
includes PDK (147, 173, 224). They showed that Akt is dispensable for T cell metabolism 
through mTOR and HIF1α, moreover,  inhibition of cytotoxic T lymphocytes (CTL) with either 
an Akt or PI3K inhibitor did not inhibit phosphorylation of S6, S6K or 4E-BP1 (147, 149, 173). 
Based on our results, we hypothesize that PDK lies upstream of PKC to induce downstream 
signaling events. PDK phosphorylates several isoforms of PKC, contributing to its activation in 
T cells.  
A fundamental question which still remains is the precise mechanism by which PKC 
regulates S6 phosphorylation through Carma1 and the MEK/ERK pathways. Our data show a 
requirement for both; however we are unable to determine whether these pathways are linked or 
if they occur independently. It is more likely that these pathways occur independently to induce 
S6 phosphorylation, as Carma1 is not required ERK activation in T cells. We propose a model 
where Carma1 and MALT1 regulate mTORC1 activation potentially through direct modification 
of the mTOR complex itself (Fig. 6-1).  
Another critical factor to be determined is the isoform(s) of PKC that may be involved 
TCR-induced S6 phosphorylation. Stimulation through the TCR and CD28 induces both the 
generation of DAG and an increase in intracellular Ca2+, through cleavage of PIP2 by PLCγ, so 
both novel and classical PKCs can be activated (4, 10). Our experiments attempting to narrow 
down the isoform responsible, using rottlerin (an inhibitor of novel PKCs), did not prove fruitful 
as it also inhibited Akt phosphorylation. It would be interesting to assess S6 phosphorylation in 
the presence of PMA (synthetic DAG analogue) but the absence of Ca2+, to determine if this is 
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sufficient to induce S6 phosphorylation comparable to PMA and ionomycin (induces release of 
intracellular Ca2+), thus differentiating between the necessity for a novel PKC or both novel and 
classical isoforms (42, 43, 162). PKC θ is one of the primary isoforms that is activated after TCR 
and CD28 stimulation, leading to activation of the NF-κB and MEK/ERK pathways, and we 
predict it also serves a similar role in activation of S6 (29). However, based on the different 
mechanisms through which PKC regulates S6 phosphorylation, we also predict that PKC θ may 
be more relevant for Carma1-mediated activation of mTORC1 and that other isoforms may 
mediate MEK/ERK-dependent S6 phosphorylation in T cells. Genetic approaches 
(siRNA/shRNA/ knockout systems) may be optimal to understand the potential differential 
requirements of PKC isoforms in S6 phosphorylation in T cells.  
 
6.2 CARMA1 AND MALT1 ARE REQUIRED FOR MTORC1 ACTIVATION IN T 
CELLS 
We show that Carma1 and MALT1 are required for activation of the mTORC1 pathway 
downstream of PKC. We are one of the first groups linking Carma1 to the mTORC1 pathway. 
Our data primarily focus on T cells, and thus we are unable to conclude if Carma1 also plays a 
significant role in mTORC1 activation in B cells. We predict that similar to our findings in T 
cells, Carma1 and MALT1 are critical for mTORC1 activation in B cells. However, due to the 
necessity of PKCβ in phosphorylation of Carma1 there may be differential signaling upstream of 
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Carma1 after B cell receptor engagement, as well as different requirements for co-stimulatory 
molecules (CD80/86, ICOSL and OX40L) (225).  
 Another member of the CARD family, Card9, also associates with MALT1 and Bcl10 in 
cells of the myeloid lineage to induce activation of the NF-κB pathway. This pathway does not 
integrate signals from antigen receptors, but rather innate receptors like Dectin, TREM, Mincle 
and NOD2 (225). Due to the nature of the activation, we hypothesize alternate signaling 
mechanisms for mTORC1 activation in these cells, through Card9 and MALT1. Additionally, we 
expect differential activation of mTORC1, depending on which receptor is activated. 
 To further understand how Carma1 is regulating mTORC1 activation in T cells, we 
would like to assess the necessity of specific domains in Carma1 that are required for mTORC1. 
Our results showing the nonobligatory role for Bcl10 in this pathway, which binds to the CARD 
domain, indicate that this may not be required, however the CARD domain may be a docking 
site for a currently unknown protein (31, 66). The coiled coil (CC) and PKC responsive (PRD) 
domains in Carma1 are both essential for downstream function as MALT1 is predicted to bind to 
the former, and the latter is necessary for activation by PKC (31, 66). The MAGUK domain is 
necessary for localization of Carma1 at the membrane, allowing for activation by PKC (31, 66). 
Carma1 is also regulated by CKI, Akt and IKKβ (31, 66), whether phosphorylation by these 
kinases is necessary for Carma1 mediated regulation of the mTORC1 has yet to be determined. 
We show that the widely expressed protein, MALT1 is also essential for mTORC1 
activation in T cells, providing another pathway that MALT1 regulates. Of note, MALT1 
inhibition (at least with z-VRPR-fmk) does not inhibit JNK activation in T cells. Currently, this 
paracaspase has been shown to regulate activation of NF-κB, c-FLIPL and the β1 integrin ligand 
fibronectin, and now the mTORC1 pathway (96, 100, 197). Functionally, this inhibition 
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translates to impaired T cell proliferation (NF-κB, mTORC1 and c-FLIPL pathways), T cell 
adhesion (Bcl10 and β1 ligand fibronectin) and T cell metabolism (mTORC1 pathway) (96, 100, 
197). Continued research in this area will be needed to define the mechanism through which 
MALT1 regulates the mTORC1 pathway, specifically identifying MALT1 substrates. None of 
the previously mentioned MALT1 targets (Table 1) have been shown to directly affect mTORC1 
activation in any cell type studied; as such, it more likely that a yet unidentified target for 
MALT1 is acting in this novel pathway.  
There may be additional roles for MALT1 beyond its paracaspase activity. It is possible 
that MALT1 serves as an adaptor protein to facilitate mTORC1 activation, leading to activation 
of S6/S6K and 4E-BP1. TRAF6, a well-characterized MALT1 associated protein, modulates 
mTORC1 activation through association and ubiquitination leading to impaired autophagy and 
cell proliferation after amino acid stimulation (226). TCR and co-stimulation may also induce 
association of TRAF6, mTORC1 and MALT1, leading to downstream function. To further 
understand possible differential requirements of the MALT1 protein or it paracaspase activity, 
assessment of transcriptional differences between MALT1 KO T cells and WT T cells treated 
with z-VRPR-fmk will need to be performed. Based on the growing recognition of the 
importance of mTOR in T cell differentiation and metabolism, focus should be placed on the role 
of Carma1 and MALT1 in controlling T cell lineage-specific transcription factors, and associated 
co-activators, as well as on genes necessary for T cell metabolism (for both oxidative 
phosphorylation and glycolysis). 
   Surprisingly, we found that Bcl10, a MALT1 binding partner, is not required for 
activation of the mTORC1 pathway, using both Jurkat T cells knocked down in Bcl10 and 
primary murine Bcl10 KO T cells. While these findings were initially confounding, as Carma1, 
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MALT1 and Bcl10 generally work as a complex to activate NF-κB and JNK pathways, work by 
Pomerantz and colleagues showed that the kinesin GAKIN competes with Bcl10 to bind the 
CARD domain of Carma1, to negatively regulate NF-κB activity (195). Of note, binding of 
GAKIN did not perturb association of Carma1 with other proteins (TRAF 6 and IKKγ) and 
translocated it from the immunological synapse (IS) (195). Bcl10 constitutively associates with 
MALT1 and is thought to stabilize MALT1 protein expression (31). In the absence of Bcl10 or 
MALT1 there is reduced expression of MALT1 or Bcl10, respectively (31). We did note reduced 
Bcl10 in MALT1 shRNA cells Fig. 4-3A), however reconstitution of these cells with WT 
MALT1 restored NF-κB activity (data not shown) (190).  
We also show that activation of NF-κB is not necessary for S6 phosphorylation (Fig. 4-
4E) a finding consistent with a very recent study using IKKβ KO T cells (227). A major goal 
which remains is understanding differential functional outcomes downstream of Carma1 and 
MALT1 leading to activation of the NF-κB versus mTORC1 pathways. Both pathways 
contribute to T cell proliferation and metabolism (4, 183, 228), e.g. IKKα regulates oxidative 
metabolism in muscle cells (229). To address whether IKK also regulates metabolism in 
activated T cells, one could perform microarray experiments in stimulated CD4+ T cells with z-
VRPR-fmk treatment, or z-VRPR-fmk in CD4+ T cells expressing constitutively active IKKβ 
(230). Utilizing these mice might allow the identification of MALT1 paracaspase-dependent 
genes that are impaired independently of NF-κB. In conjunction with these experiments, it may 
also be used to also perform microarray experiments comparing stimulated CD4+ T cells from 
Bcl10 KO mice and CD4+ T cells from MALT1 KO or Carma1 KO mice. Bcl10 is dispensable 
for TCR and CD28-dependent mTORC1 activation in T cells, so in this way differences in 
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genetic profiles between Bcl10 KO and MALT1 KO or Carma1 KO could be attributed to the 
mTORC1 pathway. 
 
 
6.3 MALT1 CATALYTIC ACTIVITY REGULATES S6 PHOSPHORYLATION IN 
ABC-DLBCL  
Understanding distinct signaling pathways downstream of antigen receptors is essential in 
unraveling the molecular mechanisms that drive disease. We show that inhibition of MALT1 is 
able to prevent stimulation-dependent S6 phosphorylation in the ABC-DLBCL sub-type. Our 
data provide evidence for additional mechanisms through which MALT1, and potentially also 
Carma1, may be driving cellular growth in this DLBCL sub-type, apart from effects on NF-κB 
(109). It would be interesting to review the genetic signature of ABC-DLBCL, previously 
ascertained by the Staudt group, for potential mTORC1 target genes (109). Several groups have 
shown that inhibition of MALT1 induces cell death specifically in the ABC-DLBCL sub-type, 
attributing most effects to inhibition of the NF-κB pathway (101, 102, 111, 114). Going forward, 
emphasis should be placed on understanding other cellular pathways that Carma1 and MALT1 
may regulate. 
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6.4 SERINE 231 OF BCL10 IS REQUIRED FOR NF-ΚB ACTIVATION IN T CELLS 
The previous chapter addresses regulation of Bcl10 in its C-terminus. We show that serine 231 is 
required for TCR and CD28 mediated NF-κB activation and IL-2 production in T cells. 
Previously published work shows Akt as the kinase phosphorylating this site, however our data 
do not confirm this finding and that inhibition of Akt does not affect Bcl10 phosphorylation 
(208). We also specifically assessed S231 phosphorylation in the presence of an Akt inhibitor, 
and no change was noted (data not shown), however inhibition with a pan-PKC inhibitor, 
inhibited phosphorylation at S231. We are unsure if PKC directly phosphorylates this site, or if 
PKC activates another kinase which directly phosphorylates S231. This site has substrate 
specificity for the AGC kinases: S6K, RSK and serum and glucocorticoid-inducible kinase 
(GSK) (188). PKC may regulate one of these kinases leading to Bcl10 phosphorylation. 
 
6.5 CONCLUSION 
We have identified a novel signaling pathway in T cells, whereby TCR and CD28 co-stimulation 
activate PKC, Carma1 and MALT1 which induces mTORC1 activation leading to T cell 
proliferation and increased metabolic output (Fig. 6-1). mTORC1 is a critical player in T cell 
activation and differentiation, through increased expression of metabolism-associated genes 
(HIF1α, c-myc amino acid transporters and glycolytic proteins) and inhibition of Foxp3 
expression (Treg signature transcription factor). Thus, understanding how this pathway is 
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activated specifically through the T cell antigen receptor is essential for our understanding of T 
cell responses to different pathogens. In the cases of aberrant T cell activation- autoimmune 
disease-identification of novel targets will provide new courses for therapies which do not fully 
cease T cell activity, and yet still provide relief from disease.  
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 Figure 6-1 Model for PKC, Carma1 and MALT1 regulation of mTORC1 activation in T 
cells. 
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